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Resumo 
As culturas primárias de hepatócitos são indispensáveis no processo de desenvolvimento de 
fármacos. Esta aplicação tem duas limitações: a reduzida proliferação dos hepatócitos e a 
rápida perda das funcionalidades hepáticas, quando cultivados in vitro. O objectivo desta tese 
foi a minimização deste último problema através da cultura de hepatócitos, como esferóides 
multicelulares, em bioreactores totalmente controlados. 
No Capítulo 1 é feita uma revisão do estado da arte em culturas primárias de hepatócitos, 
precedida de uma introdução à fisiologia do fígado e ao processo de desenvolvimento de 
fármacos. 
Inicialmente, a melhoria das culturas primárias de esferóides de hepatócitos, em bioreactor, foi 
feita com hepatócitos de ratos; Nos Capítulos 2 e 3 foram analisados os efeitos da 
microencapsulação em alginato, da cultura em perfusão e das duas estratégias em simultâneo 
na manutenção do fenótipo hepático dos esferóides; a aplicação simultânea das duas 
estratégias tem um efeito sinérgico positivo neste fenótipo hepático. 
No Capítulo 4 é feito o estudo da cultura, a longo prazo, de esferóides de hepatócitos isolados 
de 3 dadores humanos. Estes esferóides de hepatócitos responderam à administração repetida 
de fármacos, como esperado em hepatócitos maduros e diferenciados in vivo, até quatro 
semanas de cultura. 
No Capítulo 5, a cultura de esferóides multicelulares foi aplicada à maturação hepática de 
progenitores de hepatócitos, derivados de células estaminais embrionárias humanas; esta 
cultura de esferóides, quando comparada com a cultura em monocamada, levou a um aumento 
na expressão de genes hepáticos. 
No Capítulo 6 foram discutidas as melhorias na bioengenharia da cultura de hepatócitos 
possibilitadas por esta tese, bem como o possível trabalho futuro nesta área. 
Esta tese permitiu estabelecer e validar um sistema de bioreactores de perfusão que permite 
testar os efeitos de um novo fármaco, a longo prazo e com administração repetida, sobre 
esferóides de hepatócitos humanos. 
 
Termos chave: CYP450, hepatócitos, 3D, longo prazo. 
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Abstract 
The primary culture of human hepatocytes is a requirement in drug development tests. This 
application is currently hampered by two problems: the limited proliferation of the hepatocytes 
and the rapid loss of liver-specific phenotype of these cells, when cultured in vitro. This thesis 
aimed at minimizing this latter issue by cultivating hepatocytes, as spheroids, in fully controlled 
bioreactors. 
The state of the art of the primary cultures of hepatocytes is reviewed in Chapter 1, after a brief 
introduction to the liver physiology the drug development process. 
The improvement of the bioreactor cultures of hepatocyte spheroids was initially done using 
freshly isolated rat hepatocytes; the effects of alginate microencapsulation, perfusion culture 
and their synergy on the maintenance of the hepatocyte spheroids liver-specific phenotype were 
assessed in Chapters 2 and 3; it was concluded that the perfusion culture and alginate-
encapsulation had a positive synergic effect on such hepatic phenotype. 
The perfusion bioreactor developed in Chapter 3 was used in Chapter 4 for the extended 
culture of freshly isolated human hepatocytes, as spheroids, from three different donors. These 
cultures responded to repeated dose drug treatments as expected from mature and 
differentiated hepatocytes, in up to 4 weeks culture time. 
In Chapter 5, human embryonic stem cell-derived hepatic progenitors were cultured as 
spheroids and further differentiated into hepatocyte-like cells; the differential expression of 
hepatic genes between this spheroid population and a monolayer differentiated hepatocyte-like 
cell population showed a more efficient differentiation under spheroid culture. 
The bioengineering improvements of this thesis, as well as the future work, were discussed in 
Chapter 6. 
This thesis has led to the establishment and validation of primary cultures of hepatocyte 
spheroids, in perfusion bioreactors, which can be used for long-term, repeated dose tests in 
drug development. 
 
Keywords: CYP450, hepatocytes, 3D, long term. 
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1. Introduction 
 
The liver has a major role in maintaining physiological homeostasis and in detoxifying blood. In 
mammals, among other functions, it is responsible for nitrogen excretion in the form of urea, 
albumin biosynthesis (1), glucose storage in the form of glycogen, gluconeogenesis (2), 
glutamine homeostasis (3) and xenobiotic detoxification (4-7). 
1.1. Liver architecture and zonation 
The liver is composed of parenchymal cells, the hepatocytes (65% of the liver cells, 
corresponding to 90% of the liver cell mass) (8), and 4 major types of non-parenchymal cells: 
Sinusoidal endothelial, Kupffer, Stellate and Biliary epithelial cells. The main liver functionalities 
are performed by the hepatocytes, whereas the non-parenchymal cellular fraction of the liver 
supports such hepatic functions by providing nutrient and metabolite exchange (9), clear 
particulate and foreign materials from the portal circulation (10), immune protection (11) retinoid 
metabolism (12), bile and general paracrine regulation of liver function through cytokines and 
cell-cell contacts (11). The architecture of the hepatic microcirculation system, within the liver 
acinus, as depicted in Figure 1.1A, is paramount to the interactions between these different cell 
types and hepatic function. Blood, delivered by both the portal vein (nutrient rich, 75% of the 
flow) and the hepatic artery (oxygen rich, 25% of the flow) (13), flows through the sinusoids and 
leaves the hepatic microcirculation through the central vein (responsible for supplying the 
metabolized nutrients to the other organs). Nutrient exchange with the hepatocytes occurs in 
the sinusoids, which are composed of endothelial vessels with no basal lamina and 150-175 nm 
fenestrations arranged in sieve plates (Figure 1.1B). These characteristics enable an enhanced 
mass transfer of protein-bound endo and xenobiotics from the sinusoid lumen to the microvilli-
rich basolateral membrane of the hepatocytes, which are disposed in cords of 15-25 cells from 
the portal vein area to the central vein (14). The sinusoids, formed by sinusoidal endothelial 
cells (SECs), are the center of heterotypic cell-cell interactions in the liver (Figure 1.1C); Küpffer 
cells are resident macrophages which phagocyte foreign materials (such as bacterial 
endotoxins) from the portal circulation, and are located in the sinusoid lumen. Hepatic stellate 
cells (HSCs) are located in Space of Disse, between the SECs and the hepatocyte’s basolateral 
membrane. HSCs are responsible for the metabolization of retinoic compounds, vitamin A 
storage and Extracellular Matrix (ECM) production, namely collagens type I, III and IV (15). Pit 
cells, which are not represented in Figure 1.1, are Natural Killer (NK) lymphocytes resident in 
the liver which, together with Küpfer cells, are responsible for the immune response in this 
organ. 
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Figure 1.1 – The architecture of the liver: acinus (A), sinusoids (B) and the location of the different 
liver cell types in the sinusoid (C). Adapted from (13, 16) 
The by-products of the hepatic metabolization of endo and xenobiotics are excreted through the 
hepatocytes’ apical membrane into bile canaliculi which converge into the bile duct, which is 
composed by the cholangiocytes. The bile flow proceeds in countercurrent with the blood flow 
(Figure 1.1A) and the main bile duct ends in the duodenum. Bile secretion is an osmotic 
process, where the active pumping of organic solutes by the hepatocytes to the canalicular 
(apical) domain is followed by a passive inflow of water and small solutes (such as glucose), 
from the hepatocytes and through the semi-permeable tight junctions, i.e., from the Space of 
Disse (Figure 1.2). 
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Figure 1.2 – Bile canaliculi physiology; a transversal section of the hepatic sinusoid (lower figure) 
depicts the pumping of organic anions from the hepatocytes’ cytosol to the bile canaliculi. This 
solute accumulation is the driving force for paracellular water osmosis, i.e., via the semi-permeable 
tight junctions (green) between the hepatocytes. TJ – Tight junctions; BC – Bile canaliculus. Upper 
image adapted from (15). 
The microcirculation of blood in the liver acinus proceeds from the portal vein and hepatic artery 
(the periportal zone) to the central vein (perivenous zone), through the liver sinusoids where 
gas, nutrient and metabolite exchanges occur. Thus, a gradient is set in this portal/central axis 
for each molecule that is consumed or internalized by the hepatocytes (such as oxygen, Insulin, 
Glucagon or Epidermal Growth Factor (EGF) Figure 1.3 (17-19)). This gradient is accompanied 
by a compartmentalization of the hepatocytes’ functionality along the portal/central axis and is 
commonly referred to as metabolic zonation of the liver acinus. The most extreme case of such 
specialization is the ammonia metabolization mechanisms; mammals eliminate ammonia either 
by ureagenesis or glutamine synthesis. Glutamine synthetase activity, protein and mRNA are 
only present in the last 2-3 hepatocyte layers surrounding the central vein, whereas urea cycle 
enzymes (such as carbamoylphosphate synthetase) can be detected throughout the remaining 
acinus (intermediate cells between periportal and perivenous zones) up to the periportal area 
(Figure 1.3). The uptake of ammonia in the periportal hepatocytes is a low affinity/ high capacity 
binding system (due to the low affinity of carbamoylphosphate synthetase for urea, with 
Km=2mM (20)), which incorporates most of the incoming ammonia in the urea cycle; on the 
other hand, perivenous hepatocytes uptake the remaining ammonia and glutamine synthetase 
constitutes a high affinity/low capacity system (Km=0.15 mM (21)) for the ammonia substrate. 
This metabolic zonation also applies to carbohydrate metabolism (Figure 1.3), with a prevalence 
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of oxidative metabolism in the oxygen-rich periportal zone (70 mmHg/90 M O2) and an 
enhancement of the glycolytic metabolism in the oxygen poor perivenous zone (35 mmHg/45 
M O2) (18).  
 
 
Figure 1.3 – Metabolic liver zonation as a function of the (variable) zonation of oxygen, hormones 
and growth factors and of the (stable) zonation of -catenin signalling, adapted from (22). 
 
Interestingly, the metabolic zonation of carbohydrates has shown to be partially reversed upon 
retrograde liver perfusion (i.e., nutrient flow is reversed to start from the perivenous to the 
periportal zone), indicating that the hepatocytes can “sense” the oxygen concentration (for a 
review on the role of oxygen in liver zonation see (19))`. The fact that metabolic zonation is only 
partially reversed in these retrograde perfusion experiments lead to the discovery of a stable 
zonation mechanism based on -catenin signaling (23). In fact, stable zonation can also be 
seen in the non-parenchymal cell distribution and phenotype as well as in the extracellular 
matrix composition (17). 
Thus, oxygen and nutrient gradients are critical factors in the dynamic component of the hepatic 
acinus metabolic zonation, including the metabolism of xenobiotics (such as drugs) and must be 
accounted for in the design criteria of any system for primary cultures of hepatocytes. 
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1.2. Liver pathologies 
Liver tissue damage, irrespective of its etiology (viral or non-viral, autoimmune, alcoholic or non-
alcoholic hepatitis (11, 15, 24)), leads to an increased synthesis of collagen fibers by HSC and 
other fibroblast-like cell types in the liver, constituting the basic liver wound-healing process. If 
the injury is continuous, this fibrotic response typically leads to the clogging of the liver 
vasculature (namely in the sinusoids) which results in necrosis, scarring of the affected area 
and the formation of nodules of regenerating hepatocytes; the final stage of progressive liver 
fibrosis is cirrhosis (see (25) for a comprehensive review), which can also lead to the onset of 
primary hepatocellular carcinoma. These chronic clinical conditions, as well as acute liver failure 
(ALF), can result in hepatic function impairment, multi-organ failure and subsequent death, 
unless an orthotopic liver transplant (OLT) is performed (26). However, the scarcity of liver 
donors creates a logistics problem for clinical situations where OLT is recommended. The need 
to keep patients with ALF alive from the onset of the clinical symptoms until a donated liver is 
available has lead to the development of artificial (27) and bioartificial liver (28) (AL or BAL, 
respectively) devices to perform the minimal hepatic functions which are necessary for patient 
survival; while the AL devices depend mainly on plasma filtration and purification operations 
(remnant of kidney dialysis), the BAL devices typically couple plasma filtration steps to a cell-
based purification unit (i.e., a bioreactor) which can perform residual hepatic functions to sustain 
the patients lives. Irrespective of being AL or BAL devices, these solutions have not yet proved 
to be effective enough in improving ALF outcomes. In the specific case of BAL devices, the lack 
of an appropriate cellular component with significant volumetric hepatic activity is considered to 
be the major bottleneck for a clinically efficient and robust product. 
1.3. Relevance of the liver metabolism for drug development 
Bringing a new drug to the market costs upwards of 900 million USD and takes, on average, 12 
years (29). Drug development is a multistage process which typically starts with the definition of 
a biological target for a given disease; in the next stages, thousands of molecules are screened 
for binding and efficacy towards the target and lead compounds are established and optimized. 
These early stages are usually followed by the pre-clinical drug development and the clinical 
trials from phase I to III until the registration of one new chemical entity (NCE) (Figure 1.4 (30)). 
 
Figure 1.4 – Drug development workflow, adapted from (30). CD – Candidate Drug; POC – Proof of 
concept. 
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The progression along this process phases leads to a decrease in the compounds tested and 
an increase in the operation costs (i.e., clinical trials are more expensive than the pre-clinical or 
screening phases). The probability of a given candidate drug to progress from phase II to phase 
III clinical trials was about 28% from 2006 to 2007 and 18% in the period from 2008-2009; given 
that the attrition rate for a drug entering phase III is about 50% (31, 32), it has been suggested 
that the success rates of drug development are too low to cope with the increasing R&D budget 
(33). While more global and systemic analysis about the underlying reasons of this issue have 
been performed by several authors (29, 34), the concrete problems that lead to failure in phase 
II clinical trials are well documented (31): 51% of these failures were due to insufficient efficacy, 
29% to strategic reasons, 19% to pre-clinical or clinical safety issues and 1% due to inadequate 
pharmacokinetics (PK). PK can be defined as a methodology to determine a drug’s (and its 
metabolites) concentration profile along time in the human body fluids; the critical parameters 
for a PK profiling are the administration, distribution, metabolization and excretion (ADME) of 
the drug (35). The drug concentration profile in the human body is a critical variable for its 
therapeutical efficiency and since pharmaceutical companies started investing in PK pre-clinical 
research, in the early 1990’s, the failure rate in drug development owed to inadequate PK has 
fallen by 10% (30). However, the effects of a drug and it’s metabolites in the patients’ 
physiology is more difficult to assess in pre-clinical trials and such effects can lead either to 
enhanced toxicology (36, 37) or to insufficient efficacy (38). Central to these two causes of 
attrition in drug development is the biotransformation (i.e., metabolization) of the drug itself. In 
fact, according to data from Brystol-Myers Squibb from 1993 to 2006, 27% of the toxicology 
drug attrition were metabolism-related. 
The majority of drug metabolism takes place in the liver and, to a smaller extent, in the intestine, 
before reaching the systemic circulatory system (usually referred to as first pass metabolism). 
This process consists, in general, in making the drug molecule more hydrophilic to facilitate its 
excretion process. A general scheme for drug metabolization by the liver’s hepatocytes is 
depicted in Figure 1.5A, where it is implicit that drug A is passively transported through the 
hepatocytes basolateral microvilli to the cytosol. However, if the molecule is charged, it will be 
transported to the cytosol by the ATP-dependent organic anion transporting polypeptide (OATP) 
transporters (39). Within the hepatocytes, the drug will be metabolized by the phase I enzymes, 
mostly by the monooxygenase enzyme family cytochrome P450 (CYP450), which are bound to 
the membrane of the endoplasmic reticulum inside the hepatocytes; CYP450 enzymes expose 
or add functional groups (hydroxyl, thiol, amino or carboxyl) to the xenobiotic molecule. The 
resulting metabolite is then conjugated by the cytosolic phase II enzymes (even though direct 
conjugation of the non-metabolized drug is also possible, as depicted in Figure 1.5A by the 
thinner blue arrows); this group of enzymes conjugates the phase I reaction products with either 
glucuronosyl or sulfate groups by glucuronosyltransferases or sulfotransferases, respectively, or 
with other groups (for a comprehensive review of phase I and II drug metabolism see (40). 
The liver drug metabolizing enzyme expression is regulated by orphan nuclear receptors such 
as the Pregnane X Receptor (PXR), the Constitutive Androstan Receptor (CAR) or the Aryl 
hydrocarbon receptor (AhR) (41); these nuclear receptors are located in the hepatocytes 
cytoplasm and are translocated to the nucleus upon binding of the drugs, where the drug 
metabolizing enzymes’ mRNA will be transcribed at higher rates. This induction mechanism 
applies for all the enzymes ranging from phases I to III, but the phase I CYP450 enzymes have 
been found to be the most critical component of the biotransformation system, probably 
because they originate a higher variety of metabolites (42). CYP450 induction is tightly coupled 
to pharmacokinetic, safety issues and inefficacy of the drug development process by adverse 
drug reactions. Drug-drug interactions (DDI) are among such adverse reactions and Figure 1.5B 
illustrates, in a simplified way, how these interconnected drug metabolizing mechanisms can 
yield unpredicted effects: if the metabolite Y of a given drug W induces the CYP450 isoform 3A4 
which metabolizes drug A, the therapeutical effect of drug A will be offset by an increased 
clearance rate from the organism, thus leading to inefficacy of drug A or toxicity if metabolite B 
accumulates to toxic levels (41-43). Although no accurate quantifications exist, if most of these 
adverse drug reactions could be predicted during the pre-clinical phase, the potential savings by 
not taking poor candidates to clinical trials are estimated at several million dollars, excluding the 
time savings and its respective opportunity cost (36). 
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Figure 1.5 – General mechanism for drug metabolism (A) and possible drug-drug interactions (B). 
MV-microvilli. 
The studies of the NCE’s metabolization can be performed using different approaches; the 
incubation of human hepatocyte microsomes (which are lipid vesicles containing bound 
CYP450 enzymes) with the NCE yields information about the metabolites originated from the 
drug; these microsome assays are also useful to determine if the NCE or any of its metabolites 
are inhibitors of CYP450 activity (44, 45). However, the induction of CYP450 enzymes implies 
de novo mRNA synthesis, which requires intact cellular machinery and the models for these 
studies range from cells (5) to entire organisms for in vivo studies (46). These models may be 
ranked according to three main categories: throughput, predictability (relative to human 
subjects) and long term studies. 
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1.4. Models for hepatic CYP450 enzyme induction 
In vivo drug metabolism studies can be performed in large or small animal models; however, 
due to the limited throughput and high costs of larger animal models, small animal models 
(typically murines, such as rats and mice) have been used. These models enable long term pre-
clinical studies of drug metabolism, including repeated dose effects, and show the systemic 
effects of drug metabolism. Such models, listed in Table 1.1, are hampered by the consistent 
inter-species difference in drug metabolism; in fact, this low predictability towards the human 
species is the reason why FDA considers that these models may not be valuable for DDI or 
drug metabolism studies in general (47). 
Table 1.1 – Experimental models for hepatic CYP450 induction studies 
Model Type Advantages Disadvantages 
Refere
nce 
Rodents 
In 
vivo 
 Systemic 
 Long term 
 Repeated dose 
 Inter-species 
differences 
 Low throughput 
(47) 
Humanized 
Mice 
In 
vivo 
 Systemic 
 Long term 
 Repeated dose 
 Human metabolism 
(partial) 
 Endogenous 
murine factors 
crosstalk with 
human genes 
 Low throughput 
(48-50) 
Decellularized 
liver 
Ex-
vivo 
 Partial maintenance 
of liver architecture 
and vascularization 
 Human metabolism 
 Not 
characterized for 
drug metabolism 
 Complex 
workflow 
 Low Throughput 
(51, 52) 
Primary 
cultures of 
human 
hepatocytes 
In 
vitro 
 FDA and EMA 
recommended 
 All hepatic cellular 
features are present 
 Inter-donor 
variability 
 High throughput 
 Human metabolism 
 Negligible 
proliferation in 
culture 
 Liver specific 
functions decay 
within one week 
 Scarcity 
(41, 47) 
Hepatic cell 
lines 
In 
vitro 
 Availability 
 Some extent of 
human hepatic 
metabolism 
 High throughput 
 Clonal origin 
 Limited hepatic 
phenotype 
(41, 53-
57) 
Reporter cell 
lines 
In 
vitro 
 Availability 
 High throughput 
 Interference 
from the original 
cell line’s 
endogenous 
factors 
 Incomplete set 
of hepatic 
transcription 
factors 
(58) 
 
Transgenic humanized mouse models have been developed to overcome the species 
difference hurdle. Work by Ramsden and colleagues (48) demonstrated the responsiveness of 
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transgenic mice carrying a copy of the human CYP2B2 gene to phenobarbital; more recently, 
double transgenic mice carrying one copy of the nuclear receptor PXR and its downstream 
target CYP3A4 were shown to be inducible by Rifampicin, a prototypical CYP3A4 inducer in 
humans, unlike the wild-type animals (49). The current limitation of these models is the 
interaction of murine endogenous factors with the human transgenic proteins. Recently, 
modified Polyethilene Glycol hydrogels containing a primary culture of human hepatocytes, 
mouse 3T3 fibroblasts and a human liver endothelial cell line (TMNK-1) were implanted in mice 
for drug metabolism studies (50). Such ectopic bioartificial livers enable the host mice to have a 
typically human metabolism of known drugs (namely Acetaminophen cytotoxicity); with the use 
of the correct control animals, this approach may be useful for long term drug metabolism 
studies. Still, the synergy of the host’s murine metabolism with the human hepatocytes can yield 
confounding results in drugs with unknown metabolism. 
The recellularization of previously acellularized organs is a current trend in tissue engineering 
(59); this technique, which consists in the removal of cells from an organ with a detergent, yields 
the organ scaffold with a preserved ECM and vasculature. Decellularized livers from several 
species  have been successfully prepared and efficiently reseeded either with adult rat 
hepatocytes (52) or with human endothelial cells and fetal liver cells (51), respectively. Uygun 
and colleagues (52) have shown that this strategy allows to maintain primary cultures of rat 
hepatocytes for up to 2 weeks, namely drug metabolizing enzymes mRNA expression. 
However, these expression levels did not outperform those obtained by the corresponding 
collagen sandwich cultures; further improvements can be made to this system by the addition of 
non-parenchymal liver cells. In fact, the presence of SECs may be critical to re-organize the 
liver sinusoids, which are lost during the decellularization process. From a practical point of 
view, this technique is not hampered by the scarcity of livers, since cadaveric livers can be 
used.
1
 
Cell-based assays for hepatic drug induction can be divided in 3 classes: reporter cell lines for 
nuclear receptor activation, immortalized hepatocytes/ hepatoma cell lines and primary cultures 
of human hepatocytes. 
Primary cultures of human hepatocytes, either freshly isolated or cryopreserved, are FDA’s 
preferred human liver tissue for CYP450 induction tests (47). These cultures retain nuclear 
receptor, CYP450 isoforms as well as phase II and III mRNA and protein expression. This 
expression of all the major sensors and effectors of drug metabolism enables primary cultures 
of human hepatocytes to demonstrate CYP450 induction and hepatoxicity resulting from DDI. 
Primary cultures of hepatocytes have 3 main drawbacks: the hepatocytes have a negligible 
proliferation in culture, when cultured in monolayer, they lose their liver-specific activities 
(including CYP450) in less than one week (42) and these cells are scarce (even more since 
these hepatocytes do not proliferate ex vivo) and expensive, making increased throughput 
assays expensive. 
Nuclear receptor activation is the common upstream event in CYP450 de novo mRNA 
synthesis. Such a reporter system has been described by Luo and colleagues (58) based on the 
co-transfection of a hepatoma cell line, HepG2, with a plasmid with the cDNA for PXR under the 
control of a constitutive promoter and another plasmid containing the CYP3A4 regulatory region 
which controlled the expression of a reporter luciferase gene. Upon activation by a drug, the 
PXR nuclear receptor binds the regulatory CYP3A4 regions and increases the expression of 
Luciferase. This assay, which can be translated to high throughput settings, showed a fair 
correlation between PXR activation in the transfected HepG2 cells and the increase of CYP3A4 
activity in primary cultures of human hepatocytes, when exposed to prototypical CYP3A4 
inducers. However, such reporter systems are prone to interference from the endogenous 
factors from the transfected cell line and lack other transcription factors which are important for 
CYP450 mRNA synthesis. In fact, this incomplete hepatic cellular machinery is also an issue 
when the use of immortalized or hepatoma cell lines such as HepG2 or Fa2N-4 is considered 
(41). Still, there are substantial differences between immortalized cell lines: while the HepG2 
hepatoma cell line exhibits low expression levels of adult human CYP450 enzymes and high 
                                                          
1
 In the future, recellularized livers may be transplanted to hepatic failure patients, but this possibility will only become 
real if the host’s immune system does not reject the whole organ scaffold graft. In addition, it still has to be assessed if it 
is possible to reseed human liver scaffolds with a minimal functional amount of hepatocytes, for BAL applications. 
Chapter 1 – Introduction 
12 
 
levels of fetal the CYP450 (53, 54) the HepaRG cell line holds promise for hepatic drug 
induction tests. This latter hepatoma cell line was shown to express nuclear receptors and 
CYP450 transcripts at levels comparable with primary human hepatocytes (55) and its CYP450 
activity induction has been proven for the CYP450 isoforms 1A2, 2C9 and 3A4, among others, 
as well as the presence of phase II and III drug metabolizing enzymes (57, 60); such results 
make this cell line an alternative to larger throughput drug metabolism studies, since it can 
proliferate up to several passages. The main disadvantages of using the HepaRG cell line are 
its clonal origin (it originated from a hepatocellular carcinoma from one single individual (55)) 
and the co-culture nature of this system, since HepaRG cell culture contain both hepatocytes 
and cholangiocytes, making it difficult to quantify the metabolic activity per hepatocyte. The 
former clonality issue limits the assessment of the naturally occurring inter-individual variability 
in CYP450 metabolism (42, 61) when using the HepaRG model. For a mid to long term 
perspective, the differentiation of human pluripotent stem cell lines to hepatocytes is a 
promising strategy which can potentially deliver an unlimited number of terminally differentiated 
hepatocytes. Hepatic differentiation protocols have already been established (62, 63) and 
adapted to large scale culture (64), but the obtained hESC derived hepatocyte-like cells have a 
strong fetal liver phenotype, namely the expression of Alfa-Fetoprotein and CYP7A1. Further 
maturation of these cells has been a subject of several publications (65-69) showing the 
expression of mature mRNAs and protein, such as CYP3A4 (70), thus proving the potential of 
pluripotent stem cell hepatic differentiation for providing hepatocytes for drug development 
tests. 
1.5. Critical factors in long-term primary cultures of hepatocytes 
Each of the models described above has its set of strengths and weaknesses. Primary cultures 
of hepatocytes have been the subject of several works (28, 71-77) that aim at overcoming its 
short lifespan, because these cultures are still FDA’s gold standard. While some of the 
published works aim at maintaining hepatocyte viability (78), the most pursued goal of these 
works is to maintain the liver specific functionality of the hepatocytes for extended time in 
culture (79-81). 
Long term primary cultures of human hepatocytes are thus required for both drug development 
pre-clinical tests and as a biotransformation component in BAL devices; the scarcity and in vitro 
dedifferentiation of these cells are common logistic and engineering challenges for both 
applications, as depicted in Table 2: 
Table 1.2 – The logistic and engineering challenges and critical factors for the application of 
primary culture of hepatocytes to long term drug development testing and bioartificial liver 
devices. 
 Logistic Engineering 
Challenge Cell type/line Hepatic functionality 
Critical biological factors 
Availability 
Storage/cryopreservation 
Cell-cell interactions 
Cell-ECM interactions 
Soluble factors 
Dimensionality (2D or 3D) 
 
The engineering challenge for long term primary cultures of hepatocytes, i.e., the maintenance 
of hepatic functionality throughout culture time, is dependent upon critical biological factors 
which are, in fact, general barriers to obtain an in vivo-like environment when performing in vitro 
cultures. Thus, the design of the bioprocess system associated with these cultures must be 
based liver physiology principles. 
The hepatocytes in the liver are connected by tight junctions and integrate their apical surfaces 
into bile canaliculi, while sharing the same microenvironment with SECs, Kupfer and stellate 
cells; these close contacts represent the physical basis to induce effective cell-cell 
interactions, whether these are autocrine (homotypic cell interactions) or paracrine (heterotypic 
cell interactions), such as the cholesterol 7-hydroxylase (CYP7A1)-mediated bile acid 
synthesis (82) or the Transforming Growth Factor Beta (TGF-) signaling pathways (15), 
respectively. Cell-ECM interactions have a dual role in tissue engineering: they provide both 
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the appropriate substrate mechanical stiffness (83) and the ligands for cell signaling; these can 
be part of the ECM itself, such as the Fibronectin’s RGD motif, or they can simply dock at the 
ECM to be presented to the cell’s surface receptors, as is the case with Fibroblast Growth 
Factors (84, 85). Soluble factors are typically identified with the blood-dissolved nutrients (such 
as glucose, aminoacids or oxygen), metabolite products (lactate or carbon dioxide) and 
endocrine factors, such as insulin, glucagon and the glucocorticoids dexamethasone and 
hydrocortisone; the design of an appropriate culture medium is thus essential for the primary 
culture of hepatocytes. In addition, it is also necessary to ensure an efficient mass transfer to 
the hepatocytes; this is a complex challenge, since the liver is one of the most irrigated organs 
and the fenestrated hepatic sinusoid enhances the mass transfer between the blood and the 
hepatocytes beyond that of most capillary delivery systems. Moreover, since some of the liver’s 
major homeostatic functions such as the regulation of glucose levels in the blood (2) or 
glutamine synthesis (86) are based on the hepatocytes’ ability to continuously sense and act 
upon the blood’s nutrient and hormone levels, it is essential that these concentrations are kept 
fairly constant throughout culture time. 
Another characteristic of the in vivo microenvironment is the three-dimensional (3D) 
configuration; however, most in vitro cultures are performed as cell monolayers (2D). When 2D 
and 3D are compared, the main difference between these systems is the lack of symmetry in 
the cellular interactions with other cells, ECM and the culture medium soluble factors (Figure 
1.6). 
 
 
Figure 1.6 – Symmetry of the epithelial cellular interactions with other cells, the ECM and the 
soluble factors in vitro.  
The 2D symmetry spans chemical and mechanical stimuli which place this culture configuration 
apart from the in vivo microenvironment; the absence of auto or paracrine factors in the top and 
lower surface of the cell, together with a direct contact with the culture medium on the top 
surface, are the main causes for the asymmetric chemical stimulus. The absence of cells (tight 
junction binding) and matrix (integrin binding) on the top surface of the cell is the main cause for 
differences in mechanical stimulus; nevertheless, if the cellular monolayer is intact and 
continuous, these forces are at equilibrium and the cell shape may be similar to 3D or in vivo. 
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However, if there is a gap in the cellular monolayer, the nearby cells will tend to spread on the 
culture surface. 
1.6. State of the art in long term primary cultures of hepatocytes 
One of the major breakthroughs for achieving a long term primary culture of hepatocytes has 
been the collagen sandwich system (87). In these cultures the hepatocyte monolayer is coated 
with a collagen layer and the albumin secretion of these primary cultures of hepatocytes can be 
kept up to 6 weeks with the formation of bile-canaliculi like structures between the cells (88). 
The formation of the canalicular structures was suggested to be due to a reduction in cell 
spreading (due to the attachment of the cells to the top collagen layer) that increased the 
surface area of the lateral membranes of the hepatocytes available for the formation of bile 
canaliculi; this hypothesis is further reinforced be the absence of stress fibers (typical of cell 
spreading) in the actin cytoskeleton of the collagen sandwich cultured rat hepatocytes and by 
the fact that matrigel (a basement membrane-like ECM) can also be used in the sandwich 
configuration, yielding a similar performance (89). In addition, the top collagen layer also 
reduces the diffusion rate of the autocrine factors and ECM to the culture medium. 
Nevertheless, the chemical gradient between the lower surface and the top surface of the 
hepatocytes is still maintained. This limitation has been recently mitigated by the development 
of a sandwich culture system with an oxygen permeable membrane for cell attachment; while 
the lack of other nutrients has not been solved, the enhancement in oxygen availability on the 
bottom surface of the cells has lead to increased CYP450 1A activity for 4 days, when 
compared to a non-permeable surface (90). 
The perfusion bioreactor developed by Gerlach and co-workers (91) for BAL applications 
consists of three interwoven permeable capillary systems and a culture chamber; two of these 
capillary systems are for medium perfusion and each system flows countercurrently to the other 
to minimize the gradients from the fiber inlet to outlet (nutrient addition and clearance of the 
metabolic by-products, respectively), whereas the third is meant for gas exchange (O2 delivery 
and CO2 removal). This perfusion configuration is an attempt to recapitulate the intensive 
vascularization of the liver. The central culture chamber contains the liver cells (hepatocytes 
and non-parenchymal fraction), which are cultured in a compact 3D structure. This bioreactor 
system addresses all the critical biological factors for these cultures and has currently been 
scaled down from the original 800 mL working volume to 2 mL (92, 93), enabling the use of 
these devices for long-term drug development tests. However, this bioreactor does not allow 
sampling of the cells during the culture, only at its end, thus, even though it is a long term 
system for the primary culture of hepatocytes, these cells cannot be imaged throughout culture 
time nor withdrawn from the reactor to measure mRNA or protein expression. In addition, the 
hollow fiber system does not allow for accurate control of pH nor dissolved oxygen (DO) 
concentration within the fibers. 
The application of micropatterning and microfluidic techniques to design miniaturized cell culture 
devices has also been applied to primary cultures of hepatocytes, but few of these devices span 
extended culture times. The Bhatia group has designed one of the most successful microscale 
culture devices for liver cells (80); the most important design criteria for this device were the 
homo and heterotypic cell-cell interactions. Such interactions were based in hepatocyte-3T3 
fibroblast co-culture, which is known to improve the activity and maintenance of the 
hepatocytes’ liver-specific functions (94). This device was designed in a 24 well plate format to 
ensure it was user friendly; each well was micropatterned with 500 m collagen I islands and 
subsequently seeded with hepatocytes, which formed colonies on top of the collagen islands. 
Finally, 3T3 fibroblasts were seeded across the entire well to achieve the co-culture system with 
a 300 L culture volume. This system enabled the maintenance of liver-specific drug 
metabolizing activity for up to 2 weeks. This system also showed an impressive robustness, 
which may be due to the automated spotting of hepatocyte islands; nevertheless, the lack of 
control of pH and DO, both of them soluble factors, a static culture system and a limited 3D 
configuration may be the cause for the 2 week limit of these culture systems. 
Another promising microscale device for the primary culture of hepatocytes has been developed 
by the Griffith lab (95). This device has a 12 well plate format, for the above mentioned 
mentioned practical purposes. In this system, rat hepatocytes were co-cultured with liver non-
parenchymal cells enriched in SECs, thus ensuring the presence of homo and heterotypic cell-
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cell interactions. When comparing with the Bhatia group microscale device, this one has the 
additional advantage of having a dynamic perfusion system and some extent of oxygen control, 
which, being based on Computational Fluid Dynamics calculations and oxygen sensors located 
at the inlet and outlet, does not act upon an actually measured oxygen concentration sensed by 
the hepatocytes. The dynamic perfusion minimizes the gradients of culture medium soluble 
factors at the surface of the cells, which improves the transport of nutrients and products of 
metabolism but may also wash out the cell-secreted autocrine and paracrine factors, as well as 
ECM components such as fibronectin. Thus, the dilution rate set by the perfusion system must 
balance these 2 factors. In the device herein described, the dilution rate is approximately        
1.4 day
-1
,i.e., similar to that of the Bhatia group device (1 medium exchange per day), with the 
significant difference that the former device avoids sudden changes in the concentration of 
these factors (i.e., full medium exchanges). Regarding the shear stress elicited by the culture 
medium perfusion, its effect has been shown to be negligible in this specific microfluidic device 
(81), but other published works on such devices typically report flow velocity optimization to 
minimize shear stress (96). More recently, Sonntag and colleagues (97) have described a 
microfluidic reactor which has connected culture chambers for liver, brain and bone marrow 
cells; such a device may potentially allow the assessment of a more systemic response of the 
human organism to xenobiotics. 
The collagen sandwich cultures, hollow fiber bioreactors and microfludic devices have one 
limitation for long term primary culture of hepatocytes: the control of pH and DO. The main 
cause for this limitation is the difference between the oxygen concentrations in the inlets of 
fibers or microchannels (or incubator atmosphere) and the DO in the culture medium bulk. The 
use of stirred tank bioreactors with good mixing as well as pH and DO control will maintain 
steady-state concentrations of these two soluble factors in the culture medium. Our group has 
shown that this controlled system improves the culture of human hepatocyte spheroids when 
compared to stirred spinner vessels (73), which may be due to the maintenance of a 
physiological DO level in the bioreactor (approximately 60 M) (98). Primary cultures of 
hepatocyte spheroids also retain the in vivo-like 3D configuration that retains ECM and 
autocrine factors, while creating gradients from the surface to the center of the spheroid. These 
gradients have been shown not to be detrimental for the hepatocyte viability if the spheroid 
diameter is below 200 m (99), whereas spheroid diameters of 100 m enable the maximum 
specific albumin production (100). Moreover, such bioreactors have a user friendly sampling 
system (while the system set-up may require specialized bioengineering knowledge), which can 
be used for specific cell-based assays and analysis and to feed higher throughput devices (such 
as well plates). This flexibility raises the possibility of using these bioreactors for long term 
primary cultures of human hepatocytes coupled with a higher throughput analysis approach at 
each time point. 
 
2. Scope of the Thesis 
 
The main goal of this thesis was to extend primary cultures of hepatocytes for long term drug 
testing applications; while the current state of the art enables a 2 week culture of functional 
hepatocytes, their ability to synthesize CYP450 mRNA, de novo, is typically limited to the first 
week of culture. Thus, this hepatocyte potential to induce the CYP450 enzymes is the most 
demanding test used in drug development and it has been one of the most important milestones 
of this work. 
The work herein presented is the optimization of a stirred tank bioreactor system for primary 
cultures of hepatocyte spheroids (73); these bioreactors, with low shear impellers and control of 
pH, DO and temperature within the culture bulk, provide most of the above mentioned critical 
factors for the hepatocyte cultures: cell-cell interactions, cell-matrix interactions (matrix 
synthesized by the cells) and the maintenance of constant concentrations of some soluble 
factors, namely pH and oxygen (besides the 3D architecture provided by the spheroid culture). 
In chapter 2 the effect of alginate microencapsulation on rat hepatocyte spheroid cultures is 
compared to the non-encapsulated cultures; such these alginate hydrogels have shown to 
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increase the liver-specific functionality of hepatocyte spheroids, enabling the repeated induction 
of CYP1A and CYP3A isoforms during 15 and 26 days of culture, respectively. 
The bioreactor system used in rat hepatocyte spheroid cultures was further optimized by adding 
an automated, gravimetrically controlled perfusion system, which allowed the maintenance of 
stable concentrations of soluble factors. In chapter 3 the effects of this perfusion system will be 
compared with manual medium exchange, for both non-encapsulated and alginate 
encapsulated rat hepatocyte spheroid cultures. 
This perfusion bioreactor system has been applied to the primary cultures of human 
hepatocytes. In chapter 4 such cultures will be characterized and validated for long term, 
repeated dose, drug tests; the results show that this culture system maintains hepatocyte 
functionality for up to 2 weeks, and the hepatocytes CYP450 enzymes have been induced after 
7, 14, 21 and 28 days using hepatocytes from 3 different donors. In addition, the 3D architecture 
of these human hepatocyte spheroids has been investigated by confocal immunofluorescence 
microscopy, revealing a liver acinus-like polarization of the hepatocytes and the presence of 
functional bile canaliculi. 
In chapter 5 this thesis will approach the logistics problem concerning the scarcity of isolated 
human hepatocytes. The effects of both spheroid culture and alginate encapsulation in the 
hepatic differentiation of human embryonic stem cells (hESC) will be studied by comparison with 
a standard 2D differentiation protocol. 
The results described in chapters 2-5 will be thoroughly discussed in chapter 6, as well as the 
future research in this area. 
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Abstract 
The maintenance of differentiated hepatocyte phenotype in vitro depends on several factors—in 
particular, on extracellular matrix interactions, for example, with three-dimensional (3D) 
matrices. Alginate hydrogel provides the cells with a good extracellular matrix due to the 
formation of a massive capsule with semi-permeable properties that allows for diffusion of the 
medium components into the cells as well as efficient waste product elimination. 
Simultaneously, alginate protects the cells from shear stress caused by the hydrodynamics 
when cultured in stirred systems such as bioreactors. We have previously developed a 
hepatocyte aggregate 3D culture system in a bioreactor where improved hepatocyte 
functionality could be maintained over longer periods (21 days). In this work, ultra-high-viscosity 
alginate was used for hepatocyte aggregates entrapment. Hepatocyte biotransformation (phase 
I and II enzymes), CYP450 inducibility, and secretory capacity (albumin and urea production) 
were monitored. The analyses were performed in both spinner vessels and bioreactors to test 
the effect of the DO control, unavailable in the spinners. Performance of alginate-encapsulated 
hepatocyte aggregates in culture was compared with nonencapsulated aggregate cultures in 
both bioreactor (controlled environment) and spinner vessels. For both culture systems, 
hepatocytes' metabolic and biotransformation capacities were maintained for up to 1 month, and 
encapsulated cells in bioreactors showed the best performance. In particular, albumin 
production rate increased 2- and 1.5-fold in encapsulated aggregates compared with 
nonencapsulated aggregates in bioreactor and spinner vessels, respectively. Urea production 
rate increased twofold in encapsulated cultures compared with nonencapsulated cells, in both 
bioreactor and spinner vessels. Similarly, in both the bioreactor and the spinner system, cell 
encapsulation resulted in a 1.5- and 2.8-fold improvement of hepatocyte 7-ethoxycoumarin and 
uridine diphosphate glucuronosyltransferases (UGT) activities, respectively. For all parameters, 
but for UGT activity, the bioreactor system resulted better than the spinner vessels; for UGT 
activity no difference was observed between the two. Furthermore, both encapsulated and 
nonencapsulated 3D culture systems were inducible by 3-methylcholanthrene and 
dexamethasone. The encapsulated systems consistently showed improved performance over 
the nonencapsulated cells, indicating that the protection conferred by the alginate matrix plays a 
relevant role in maintaining the hepatocyte functionalities in vitro. 
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1. Introduction 
 
Primary cultures of hepatocytes constitute a well-accepted in vitro model system for studies of 
drug metabolism, enzyme induction, cell transplantation, viral hepatitis studies, and hepatocyte 
regeneration. However, such cells grown in culture undergo rapid loss of differentiated functions 
and do not proliferate swiftly (1, 2). 
Innumerous attempts have been made to culture hepatocytes in an environment that supports 
functional longevity and where cells more closely reflect characteristics of the liver in vivo. The 
difficulty has been in maintaining hepatocyte cultures that show differentiated characteristics 
and maintain metabolic rates comparable with physiological liver functions over long periods. 
Approaches that have been explored include choice of hormonally defined media for the 
maintenance of differentiated functions (3-5), cultured on different types of extracellular matrix 
(ECM) molecules (6, 7), use of cocultures with nonparenchymal liver cells(8), the addition of 
molecules that are able to improve expression of a differentiated phenotype(9), and a 
combination of several of these conditions to realize in vitro hepatic organoids (10). Such 
techniques are of great help; however, for the development of bioartificial organs(11), besides 
the need of optimal hepatocyte functional and structural integrity and efficiency, a large amount 
of liver-like tissue is necessary(12).  
Since organisms have a three-dimensional (3D) spatial organization and cells in organs are 
exposed to nonuniform oxygen and nutrient distributions as well as physical and chemical 
stresses, it is expectable that hepatocytes grown as two-dimensional (2D) monolayers have 
less complex intercellular and cell–matrix interactions compared to their real physiological state. 
Thus, in the last two decades efforts were made to develop 3D cell culture models bridging the 
gap between cell-based assays and animal studies(13). Among the several types of 3D cell 
models that have been developed, the hepatocyte aggregate model, consisting on cell 
aggregates of 100–500 μm, has been increasingly gaining recognition in the biomedical 
research field(14-17).  
One concern when using aggregates is that they can experience strong shear stresses, which 
may affect cell physiology, and the system could hardly be used in clinical applications due to 
cell aggregate unprotected nature. Within the human body, cells like hepatocytes interact with 
neighboring cells and ECM components to establish a complex communication network of 
biochemical and mechanical signals. On the basis of these facts, hydrogel matrices that provide 
physical support for cells' self-assembly have been adopted. Among the biopolymers used in 
biotechnological and medical applications, alginate has been one of the most successful. 
Distinct but interrelated factors substantiate the cells' enhanced performance in alginate: ECM, 
coculture with nonparenchymal cells, maintenance of cell morphology, cell-to-cell contact with 
expression of intercellular contact zones and polarity, and aggregation into multi-layers may all 
enhance survival and performance of encapsulated hepatocytes compared to monolayer 
cultures on simple substrata(18).  
Presently, selection of the hydrogel scaffold methods has been largely based on material 
availability. However, properties like biodegradability and biocompatibility became a major 
concern due to the need to immobilize hepatocyte aggregates for tissue engineering and to 
generate bioartificial organs(19). Therefore, in this work, a clinical-grade, biocompatible, 
immunologically inert, highly purified alginate of extremely high viscosity (>30 mPa · s; 0.1% w/v 
solution) extracted by a novel process in a good manufacturing practices (GMP) amenable 
facility and uniformly cross-linked with Ba2Cl (19) has been adopted. Simultaneously, this 
alginate provides the cells with a good, thermostable ECM forming a semi-permeable 
membrane that allows for diffusion of the medium contents to the cells and for product 
elimination. 
Finally, aggregate culture requirements are substantially higher than those of 2D cultures grown 
in static conditions since diffusion of nutrients and oxygen should not be limited. Bioreactors 
were primarily developed to optimize mass transfer, a crucial element for guaranteeing 
gas/nutrient supply and waste elimination, essential factors for maintaining cell viability within 
3D cell tissue cultures(20).  
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On the basis of this prior concept, we herein describe a novel 3D culture strategy based on the 
cultivation of hepatocyte aggregates encapsulated in such alginate matrices under a totally 
controlled environment bioreactor. This system combines the advantages of a 3D culture 
system in alginate gel, controlled oxygen supply, and homogeneous and well-defined culture 
conditions with the possibility of high throughput and automation. Within this context, for culture 
characterization, hepatocyte biotransformation and metabolic capacity were assessed. In 
particular, phase I (7-Ethoxycoumarin [ECOD] and testosterone hydroxilation) and phase II 
(uridine diphosphate glucuronosyltransferases [UGT]) activities and induction measurements 
will be performed as well as albumin and urea quantifications. 
 
2. Material and Methods 
 
2.1. Rat hepatocyte isolation  
Male Wistar rats (6–9 weeks old, 200–300 g body weight) kept on a standard diet with free 
access to water were obtained from Instituto de Higiene e Medicina Tropical Animal House, 
Lisbon, Portugal. For surgery the animals were anesthetized with an intraperitoneal injection of 
ketamine (90 mg/kg body weight) and xylazine (10 mg/kg body weight) solution. 
Hepatocytes were isolated by the two-step collagenase perfusion method described by 
Seglen(21), with slight modifications. Briefly, the liver was perfused in situ, via portal vein, for 
7 min with a Perfusion Buffer I (0.14 M NaCl, 6.7 mM KCl, and 10 mM HEPES with pH 7.5 
adjusted with 2.4 M EGTA) at 39°C. Subsequently, perfusion was continued with a collagenase 
(10 mg/100 g body weight) containing buffer (67 mM NaCl, 6.7 mM KCl, 100 mM HEPES, 
albumin (0.5%), and 4.8 mM CaCl2, adjusted to pH 7.6) at 39°C for 4 min. The flow rate for the 
perfusion buffers was 10 mL/min. After perfusion the liver was removed from the animal and 
dissociated in cold Perfusion Buffer I with 10 g/L of albumin. The resultant cell suspension was 
filtered through gauze, centrifuged for 10 min at 50 g, washed once with the medium, 
centrifuged again, and resuspended in the cold medium for a final concentration less than 
3.5 × 10
6
 cell/mL. For the enrichment of the final hepatocyte population, an additional Percoll-
step was included. Five milliliters of cell suspension was layered over a 25% Percoll solution 
and centrifuged at 1300 g at 4°C for 20 min, and the hepatocytes were obtained as a pellet. The 
cell pellet was diluted in phosphate-buffered saline (PBS), centrifuged for 10 min at 50 g, and 
washed twice with PBS for removing the Percoll solution. Finally, the cells were harvested in 
supplemented Williams'E medium for culturing. Cell viability was assessed by the trypan blue 
exclusion test and was, routinely, within an 85%–95%. 
2.2. Cell culture  
Freshly isolated hepatocytes were cultured with Williams'E medium supplemented with 10% 
fetal bovine serum (FBS) (v/v), 1.4 μM hydrocortisone, 0.032 U/mL insulin, 15 mM HEPES, 
1 mM sodium pyruvate, 1 mM NEAA, antibiotics 100 U/mL penicillin/100 μg/mL streptomycin, 
and 40 μg/mL gentamicin—designated as Williams'E complete medium. 
In 2D cultures (static monolayer cultures) cells were seeded onto Matrigel
®
-precoated culture 
plates at a density of 5 × 10
4
 cells/cm
2
. Hepatocytes were left untreated for at least 12 h at 37°C 
in a humidified atmosphere with 5% CO2 in air, allowing cell attachment. The medium was 
changed the following day to remove unattached cells. The culture medium was renewed every 
24 h and the cells were routinely examined under phase-contrast microscopy before every 
culture medium renewal. 
In 3D cultures (stirred tank cultures), single-cell suspensions were seeded in 125 mL spinner 
vessels or in a 250 mL stirred tank bioreactor. To promote cell aggregation, 15 × 10
6
 cells or 
30 × 10
6
 cells were inoculated in 70 or 200 mL in the spinner vessels or in the bioreactor, 
respectively, with supplemented medium at 15% FBS. Stirred tanks were agitated at 
80 rotations per minute (RPM), and kept at 37°C in a humidified atmosphere of 5% CO2 in air for 
24 h. After 24 h, 50% culture medium was changed, added to a final culture volume of 125 mL or 
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250 mL in the spinner vessels or in the bioreactor, respectively, and the FBS concentration was 
adjusted to 10% (v/v). To maintain the aggregates, the operational mode applied was a 50% 
medium substitution (refeed mode) every 4 days, for nutrient availability and to decrease the 
accumulation of bioproducts of cellular metabolism that can be toxic to the cells. 
The supernatants and cells were collected according to the protocol at the indicated time points 
and stored at −20°C for further assays. 
2.3. Entrapment of hepatocyte aggregates in alginate  
Ultra-high-viscosity, clinical-grade alginates (viscosity of a 0.1% [w/v] solution in distilled water 
was 20–30 mPa · s) were collected in Coquimbo, Chile, and extracted in a GMP-amenable 
facility at the Fraunhofer IBMT (Sulzbach, Germany) separately from stripes of Lessonia 
nigrescens and Lessonia trabeculata as described by Zimmermann et al (19). A 1:1 mixture of 
those alginates was used at 0.4% or 0.7% (w/v) in 0.9% NaCl solution. 
For alginate entrapment, hepatocyte aggregates were suspended in the mixture described 
above to obtain the desired cell density per mL of alginate. Cell suspension was dropped 
through a syringe-based apparatus into an isotonic polymerization solution containing 20 mM 
BaCl2 (pH 7.3). After 15–20 min of incubation, the resulting spherical beads (mean size 
400 ± 100 μm) with entrapped hepatocyte aggregates were washed in 0.9% NaCl solution, 
suspended in Williams'E complete medium, and transferred to the stirring vessel (spinner or 
bioreactor). 
2.4. Cultures in the bioreactor  
To ensure a fully controlled cell culture environment, a commercially available bioreactor, 
500 mL Sartorius-Stedim Biostat Q-Plus system, with a three-blade segment stirrer was used. 
The internal geometry of each vessel is similar to the commercially available spinner vessels, 
although it has a marine impeller, in contrast to the paddle impeller of the spinners. The 
bioreactors have multiple (up to 12) upper cap ports for different applications, such as pH and 
DO meters, that allow online measurement and control of these parameters, easy sampling, 
and the addition or removal of medium or other supplements or solutions. The pH and DO were 
controlled via surface aeration with air, N2 (for DO), and CO2 (for pH). The pH was kept at 7.4 
and the DO at 30%. The temperature was kept at 37°C by water recirculation in the vessel 
jacket controlled by a thermocirculator bath. The bioreactor controller unit was used to monitor 
and control pH, DO, and temperature. Data acquisition and process control were performed 
using MFCS/Win Supervisory Control and Data Acquisition (SCADA) software (B-Braun Biotech 
International GmbH). 
2.5. Cell counting  
Alginate beads were dissolved by incubating in Na2SO4 1 M, pH 7, at 37°C for 20 min. Released 
aggregates were digested with trypsin, and single cells' viability was assessed using trypan blue 
exclusion method. Cell were counted using a Neubauer counting chamber, and data calculated 
as percentage of cell survival considering cell number at day 1 as 100%. 
2.6. Determination of albumin secretion and urea synthesis  
The secretion of albumin from hepatocytes was measured by an enzyme-linked immunosorbent 
assay using NEPHRAT albumin test kit (ref.NR002; Exocell). The assay was performed 
according to the manufacturer's description. The results were expressed as μmol/10
6
 cells/day 
at the indicated time point. 
The urea synthesis rate was determined using a quantitative colorimetric urea kit 
(QuantiChrom™ Urea Assay Kit, DIUR-500, ref DIUR-500; BioAssay Systems), according to the 
manufacturer's instructions. The results were expressed as μmol/10
6
 cells/day at the indicated 
time points. 
2.7. CYP450 measurement  
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ECOD activity was measured according to Gomez-Lechon et al (22). with slight modifications. 
Salicylamide (1.5 mM) was added to the medium to prevent conjugation of 7-hydroxy 
metabolites of ECOD (23); therefore, hydroxilation treatment with β-glucuronidase/arylsulfatase 
was not necessary. The activity refers to 7-hydroxycoumarin formed and is expressed as 
μmol/10
6
 cells/h. 
Testosterone is regio- and stereoselectively metabolized by CYPs to several hydroxylated 
metabolites that were extracted and analyzed. In this study 4-androstene-3,17-dione 
(androstenedione) and 2α,7α, and 16β-hydroxytestosterone were analyzed. Briefly, 250 μM 
testosterone dissolved in the culture medium was added to cells and incubated for 2 h at 37°C. 
Hydroxylated metabolites were extracted from cell culture supernatant with dichloromethane. 
After centrifugation (2000 g for 5 min), the organic phase was collected in a new clean tube and 
allowed to evaporate. The pellets were resolubilized in a mixture of methanol–water (50%/50%, 
v/v) for high-performance liquid chromatography analysis. Separations were performed on a 
250 × 4 mm RP18 Lichrocart, 5 μm column using a Merck Hitachi LabChrom Elite 
chromatograph equipped with an autosampler, column oven, and diode array detector. Data 
were analyzed using EZChrom Elite data system. 
2.8. UGT activity  
The UGT activity was determined by quantification of the substrate, 4-Methylumbelliferone (4-
MU), before and after cell incubation with the substrate. The procedure was performed 
according to Gomez-Lechon et al (22). with slight modifications. Briefly, a 100 μM solution of 4-
MU in 0.01 M PBS was incubated with cells for 1 h at 37°C. The 4-MU remaining concentration 
was determined based on a standard curve generated in PBS spiked with 0, 1.56, 3.12, 6.25, 
12.5, 25, 50, and 100 μM. The activity refers to 4-MU metabolized and is expressed as μmol/10
6
 
cells/h. 
2.9. Induction assay  
To evaluate the induction potential of 3-methylcholanthrene (3-MC) and dexamethasone, on the 
biotransformation-involving enzymes, hepatocytes were exposed to the compounds for 72 h 
periods at 37°C on days 2 and 8, and on days 4, 12, 18 of culture, respectively. 
3-MC (Supelco) stock solution in dimethyl sulfoxide (2.5 mM) was diluted in Williams'E complete 
medium to obtain the working solution with a final concentration of 2.5 μM. Dexamethasone 
(Sigma) stock solution in ethanol (50 mM), on the other hand, was diluted in Williams'E 
complete medium to obtain a working solution with a final concentration of 50 μM. In 2D cultures 
(24-well plates), the reaction was initiated by the addition of 500 μL of test item working solution. 
For 3D cultures 250 μL of each compound stock solution was added to the 250 mL bioreactor 
3D culture, resulting in a final concentration of 2.5 and 50 μM of 3-MC and dexamethasone, 
respectively. Cell concentration in each culture system was as described above. The activity of 
CYP3A was quantified with a luciferin-6′ pentafluorobenzyl ether using a luciferase assay from 
Promega (P450-Glo™ assays) according to the manufacturer's instructions. 
2.10. Statistics  
The data presented for the different culture parameters represent mean values for three 
independent experiments with two determinations each. Comparison of mean values between 
2D monolayer, 3D spinner, and 3D bioreactor cultures, as well as the effect of inoculum 
concentration study, was performed using an appropriate one-way analysis of variance test. 
Multiple comparisons between groups in each case were performed using a Tukey's honestly 
significant difference test. A level of confidence of α = 0.05 was chosen for all tests, with p-
values lower than 0.05 considered to be statistically significant. 
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3. Results 
 
3.1. Effect of cell inoculum and alginate concentration on hepatocytes functionality  
To optimize encapsulation parameters and evaluate the effect of alginate entrapment of rat 
hepatocyte aggregates on cell metabolism, conditions such as inoculum concentration 
(0.5 × 10
6
, 1 × 10
6
, 3 × 10
6
, and 10 × 10
6
 cells/mL of alginate) within the alginate beads and 
alginate concentration (0.4% and 0.7%) were investigated first. 
Specific hepatocyte cellular functions were assessed, namely, albumin and urea secretion and 
phase I (such as CYP450) enzyme activity. All the cultures were kept for 10 days and 
performed in Petri dishes under orbital shaking conditions. The feeding strategy used was to 
replenish 50% of the culture medium every 4 days. 
Before encapsulation, hepatocytes were cultivated in suspension to form aggregates as 
described in the Materials and Methods section. Within the first 24 h after inoculation, the cells 
aggregated into clusters and small aggregates began to rearrange, changing from irregular 
shapes into a more compact spherical form until they reached approximately 100–200 μm in 
diameter after 2 days of culture. The increase in size of the aggregates is predominantly due to 
aggregation, as no evidence of significant hepatocyte proliferation has been found under such 
conditions. At day 2 of culture, aggregates were encapsulated in alginate. 
To evaluate the effect of alginate concentration on hepatocyte functionality, two inocula 
concentrations (1 × 10
6
 and 10 × 10
6
 cells/mL of alginate) were examined using 0.4% and 0.7% 
alginate. Very few changes on aggregate morphology and viability were observed under 
microscopic examination; however, an increase in the size of the capsules (Figure 2.1) was 
observed after 1 week of culture when 0.4% alginate was used. At day 8 of culture the 
production of albumin and urea declined dramatically within the 0.4% alginate cultures as 
shown in Figure 2.2A and B, whereas cultures with 0.7% alginate and 1 × 10
6
 cells/mL of 
alginate kept the ability to secrete albumin and urea until the end of the culture period. Similarly, 
cultures with 1 × 10
6
 cells/mL of alginate within 0.7% alginate beads resulted not only on higher 
ECOD activity levels, but also in the maintenance of such levels during the whole culture period 
of 10 days (data not shown). 
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Figure 2.1– Phase-contrast microscopy (amplification of 100 × ) of encapsulated hepatocyte 
aggregates in 0.7% alginate using an inoculum of (A) 10 × 10
6
 or (B) 1 × 10
6
 cells/mL alginate, and 
0.4% alginate using an inoculum of (C) 10 × 10
6
 or (D) 1 × 10
6
 cells/mL alginate. Samples collected at 
day 8 of culture. 
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Figure 2.2 – Functional capacity of hepatocytes assessed by determining (A) urea production and (B) albumin 
secretion when cultured as encapsulated aggregates in 0.4% alginate with an inoculum of 1 × 10
6
 cells/mL of 
alginate (white bars) or 10 × 10
6
 cells/mL of alginate (hatched bars), and 0.7% alginate with an inoculum of 1 × 10
6
 
cells/mL of alginate (black bars) or 10 × 10
6
 cells/mL of alginate (gray bars). 
 
The quantity of hydroxytestosterone (OHT) metabolites produced by cultured hepatocytes was 
monitored as well. It varied depending on the metabolite (2α-OHT, 7α-OHT, and 16β-OHT and 
androstenedione) and the culture conditions. Metabolite production during cultivation is 
presented for the four culture systems at days 3 and 6 of culture (Table 2.1), showing higher 
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testosterone hydroxylation for 0.7% alginate-cultured hepatocytes. In particular, the metabolism 
of testosterone to 2α-OHT and 16β-OHT was higher in the 1 × 10
6
 cells/mL alginate cultures, 
whereas that to 7α-OHT and androstenedione was higher in the 10 × 10
6
 cells/mL alginate 
cultures. 
 
Table 2.1 – Activities for Region and Stereospecific Testosterone Hydroxylation of Encapsulated Hepatocyte 
Aggregates in 0.4% or 0.7% Alginate Using an Inoculum of 1 × 10
6
 or 10 × 10
6
 Cells/mL Alginate. Data are means of 
two independent experiments. 
 μmol/10
6
/h 
Time (days) 
0.4%/1 × 10
6
 
cells 
0.4%/10 × 10
6
 
cells 
0.7%/1 × 10
6
 
cells 
0.7%/10 × 10
6
 
cells 
Testosterone metabolite 2 6 3 6 3 6 3 6 
2α-hydroxytestosterone 0.93 0.02 0.56 0 5.93 0 0.23 0 
7α-hydroxytestosterone 1.31 0.74 0.20 0.14 24.03 13.55 55.80 26.85 
16β-hydroxytestosterone 3.93 2.01 0.87 0 165.78 125.20 18.28 15.93 
Androstenedione 5.32 3.00 3.58 0.78 134.52 121.74 961.59 144.42 
 
In conclusion, the results show that 0.7% alginate with an inoculum of 1 × 10
6
 cells/mL alginate 
is the best option for improved cell cultures. 
Subsequently, further inoculum concentrations were investigated using the 0.7% alginate, 
namely, 0.5 × 10
6
, 1 × 10
6
, and 3 × 10
6
 cells/mL of alginate. The later inoculum corresponds to 
1.2 × 10
5
 cells/mL of the culture medium optimized previously for nonencapsulated aggregate 
cultures (17). Herein, the encapsulated aggregates' performance in culture was evaluated 
against nonencapsulated aggregate cultures with a 1.2 × 10
5
 cells/mL inoculum and 2D 
conventional cultures in static conditions (monolayer). 
For these experiments, urea and albumin production and ECOD activity were on average 2.4-, 
1.5-, and 3.4-fold greater for the 1 × 10
6
 cells/mL alginate culture than in 3 × 10
6
 cells/mL 
alginate cultures, respectively. On the other hand, no significant (p > 0.05) differences could be 
observed between the 1 × 10
6
 cells/mL alginate and 0.5 × 10
6
 cells/mL alginate cultures except 
for urea secretion, which was 1.6 times higher in the 1 × 10
6
 cells/mL alginate cultures. 
Moreover, in the 0.5 × 10
6
 cells/mL alginate cultures, hepatic functions could no longer be 
detected after day 9. Encapsulated cultures resulted in improved differentiated functionality 
compared to the nonencapsulated aggregate cultures. 
In summary, encapsulated aggregate cultures, with an inoculum of 1 × 10
6
 cells/mL alginate in a 
concentration of 0.7%, resulted in enhanced hepatocyte functionality over all other systems 
tested. 
3.2. Scale-up: Encapsulated aggregates cultures in spinner vessels and bioreactor  
An inoculum of 1 × 10
6
 cells/mL alginate in 0.7% alginate was used in the bioreactor, where 
parameters such as pH, temperature, DO, and agitation rate could be continuously monitored 
and controlled (Figure 2.3). 
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Figure 2.3 – Sartorius-Stedim Biostat Q-Plus Bioreactor system used in hepatocyte three-dimensional cultures. A 
maximum of three vessels can be used in parallel. 
 
The cultures were maintained for 1 month with the same feeding strategy used previously, that 
is, 50% culture medium replenishments every 4 days. As controls, encapsulated and 
nonencapsulated aggregates (1.2 × 10
5
 cells/mL inoculum) were cultivated in parallel in spinner 
vessels as well as 2D monolayer cultures. 
As expected, bioreactor cultures resulted in higher albumin and urea rates, with albumin 
production rate peaking at day 11 of culture; for spinner vessels, albumin production rates 
decreased during culture, reaching residual levels at days 16 and 12 in capsules and 
aggregates, respectively. Albumin production rate showed 100% and 50% improvement in 
encapsulated aggregates compared to nonencapsulated aggregates in bioreactor and spinner 
vessels, respectively, whereas urea production rate was increased twofold in encapsulated 
versus nonencapsulated cultures in both spinner vessels and the bioreactor experiments. 
Hepatic metabolic function was assessed by determining the phase I (ECOD) and II (UGT) 
enzymes. When UGT activity was analyzed, no significant (p  > 0.05) differences could be 
observed between spinner and bioreactor systems, but encapsulated hepatocytes had 2.8 times 
higher activity than nonencapsulated aggregates (Figure 2.4B). Conversely, significantly higher 
(p < 0.05) ECOD activity levels (Figure 2.4A) were observed in encapsulated aggregates 
cultured in the bioreactor in comparison to all other 3D culture systems. 
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Figure 2.4 – (A) ECOD and (B) UGT activities in rat hepatocytes cultured as encapsulated aggregates in bioreactor 
(––) and spinner (––); nonencapsulated aggregates in bioreactor (––) and spinner (––), and as monolayer 
(–x–), 2D. 2D, two-dimensional. ECOD, 7-ethoxycoumarin; UGT, uridine diphosphate glucuronosyltransferase. 
 
As secondary observations, nonencapsulated aggregates cultured in the bioreactor resulted in 
ECOD activities similar to the encapsulated aggregates cultured in spinner vessels, leaving the 
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nonencapsulated aggregates cultured in spinners with the lowest ECOD activities of all the 3D 
culture systems evaluated; the 2D cultures showed the lower phase I and II enzyme activities. 
3.3. Proof of concept and validation  
To validate the culture system, the effects of 3-MC and dexamethasone, known inducers of rat 
CYP1A1/2A1/2B and CYP3A, respectively, were evaluated; the induction periods lasted 72 h 
each. Noninduced cultures (encapsulated and nonencapsulated aggregates) and 2D cultures 
were carried out as controls. CYP3A activity was monitored using the P450-Glo™ CYP3A4 
Assay (Promega; V8901), while CYP1A1/2A1/2B activity was analyzed by ECOD. 
After the addition of 3-MC, induction of ECOD activity in both systems was assessed (Figure 
2.5). In 2D cultures, induction of ECOD activity was only obtained with the first addition of the 
inducer being 1.4-fold greater than the noninduced cultures. For the 3D hepatocyte systems, 
exposure to 3-MC resulted in a marked increase of ECOD activity, and peak activities were 
observed on days 3 and 10, with 1.6-fold and 2.1-fold greater induction over the noninduced 
activity, respectively. Comparison of the inducibility of ECOD activity by 3-MC in both 2D and 3D 
systems revealed a 50% (p < 0.05) higher effect of the inducer on the enzyme activity in the 3D 
versus 2D. 
 
 
Figure 2.5 – 3-Methylcholanthrene induction of CYP450-dependent activity in primary culture of rat hepatocytes. 
ECOD activity was measured in induced encapsulated aggregates (––), induced aggregates (––), noninduced 
aggregates (––), induced 2D cultures (–X–), and noninduced 2D cultures (–x–). Induction periods were 72 h 
starting on days 2 and 8 of culture. 
 
Similarly, induction of CYP3A in 4-, 12-, and 18-day-old rat cultures with dexamethasone 
resulted in a greater maintenance of CYP3A activity observed in the three cycles in both 
encapsulated and nonencapsulated 3D culture systems. As shown in Figure 2.6, increased 
activity levels were obtained in the encapsulated system compared to the nonencapsulated 
aggregates, with activities 1.3, 1.8, and 1.6 times higher in the first, second, and third induction 
cycles, respectively. No difference was observed between 2D control cultures treated with or 
without inducer; that is, no induction took place in the monolayers. 
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Figure 2.6 – Dexamethasone induction of CYP450-dependent activity in primary culture of rat hepatocytes. 
CYP450 3A activity was measured in induced encapsulated aggregates (––), noninduced encapsulated 
aggregates (––), induced aggregates (––), noninduced aggregates (––), induced 2D cultures (–X–), and 
noninduced 2D cultures (–x–). Induction periods were 72 h starting on days 4, 12, and 18 of culture. 
 
It is noteworthy that rat hepatocyte CYP450 could be induced in all 3D cultures by 3-MC and 
dexamethasone. 
 
4. Discussion 
 
In this work we aimed at developing a hepatocyte culture system with functional cells over a 
long period (1 month). For this purpose, a 3D system consisting of rat hepatocyte aggregates 
encapsulated within alginate beads cultured in a scalable and commercially available bioreactor 
was used. 
As stated in Introduction and Results sections, we compared here encapsulation using alginate 
versus nonencapsulated 3D systems, with 2D monolayers as controls. Fully controlled 
bioreactors were tested also against spinner vessel cultures. Commercially available alginate is 
often of high variability; thus, in this work we used a well-characterized GMP-grade alginate that 
shown previously good results for encapsulation of several cells types (24-26). The major 
advantages of our strategy of the 3D encapsulation over other reports concerning the use of 
alginate for hepatocyte culture (12, 27-30) is that we have used hepatocyte aggregates that 
further promote cell-to-cell contact rather than encapsulating single cells (28); further, the 
alginate used is of clinical grade, meeting the various demands for a long-term 
immunoprotecting encapsulation matrix for transplantation (19); finally, cells were cultured in a 
fully controlled commercially available bioreactor. 
Herein, the capsule size was kept below 400 μm, cell density optimized to 1 × 10
6
 cells/mL 
alginate, and alginate percentage optimized to 0.7%; in fact, previous observations indicated 
that the latter diameter approaches the upper diffusion limit for maintaining hepatocyte viability 
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(18). The uncontrolled swelling of 0.4% alginate capsules may be due to the weaker alginate 
network compared with 0.7% alginate matrices, which can withstand the osmotic pressure 
occurring between gel and the surrounding solution (25).  
The use of complex extracellular substrates has been reported to play a key role in the 
maintenance of biotransformation and metabolic system of hepatocytes. In this work, monitoring 
of albumin and urea production (31) and ECOD and UGT activities(32) was performed to 
evaluate cell function and biotransformation, respectively. As shown here rat hepatocyte 
aggregates encapsulated within an alginate matrix exhibited remarkably enhanced expression 
of all the parameters analyzed, mainly when cultivated in fully controlled bioreactors. Since 
oxygen supply is critical for the adaptation of hepatocytes to culture and it decreases within 
alginate beads depending on size and entrapped cell density (12), the continuous oxygen flow 
enabled by the bioreactor revealed to be a decisive factor in maintaining hepatocytes 
functionality. However, UGT activity was improved in the encapsulated cultures, regardless of 
the culture vessel used (bioreactor or spinner), meaning that, in this case, the key factor was 
the encapsulation. 
In the case of urea production or ECOD activity, similar performance was observed on 
encapsulated cells cultured in spinner vessel and on nonencapsulated cells cultured in 
bioreactor. Thus, the data obtained in this study suggest that hepatocyte cultivation within 
alginate microbeads not only resulted in a clear increase of hepatocyte-specific functions tested 
in vitro, but also significantly improved spinner effectiveness in urea production and ECOD 
activity. These results are in accordance with previously reported data(9, 18, 28). 
Another concern when developing new in vitro hepatocyte cultures is that hepatic metabolism of 
drugs is frequently the cause of adverse drug interactions. Induction of CYP450 enzymes is 
clinically important because it can modify the metabolism of drugs. It can potentiate their 
pharmacological action, diminish their efficacy, or produce unexpected hepatic side effects (33). 
The response of hepatic biotransformation enzymes to the action of classical in vivo inducers 
can easily be studied in vitro by exposing cultured hepatocytes to chemicals. In this study, 
treatments were initiated once the cells stabilized, that is, 24 h after encapsulation, and were 
prolonged for 72 h. This exposure time was sufficient to bring about the effects of moderate to 
strong drug-metabolizing enzyme inducers. The presence of dexamethasone in culture media 
increases CYP3A activity in rat hepatocytes selectively, namely, CYP3A1 and 3A23, the 
ortholog of the human CYP3A4 (34). In contrast, ECOD activity depends on different isozymes, 
including CYP1A1, 2A1, 2B1, and 2B2, and it is induced by 3-MC or Phenobarbital (35). Using 
this in vitro model, an increase in total CYP450 levels produced by both dexamethasone and 3-
MC was observed. ECOD and CYP3A activity studies demonstrated that the 3D culture systems 
studied responded to all the induction insult. For CYP3A inducibility, alginate entrapment of 
hepatocytes aggregates significantly enhanced CYP induction compared to the 
nonencapsulated system. 2D cultures were not inducible. In in vitro cultures, the metabolism of 
testosterone to different hydroxyl metabolites is reduced by 90% in human hepatocytes after 2 
days in culture(36). Thus, it is expectable that no activity is detected at day 5 of culture, that is, 
already at the first induction period. Regarding 3-MC induction, it should also be highlighted that 
although both encapsulated and nonencapsulated aggregates had similar induction levels, 
higher ECOD activities during the noninduced periods were observed in encapsulated 
aggregates, suggesting that the ECM provided by the alginate entrapment conferred the 
hepatocytes an advantageous culture system. Regarding 2D cultures, they only responded to 
the first induction by 3-MC, whereas no induction was observed with dexamethasone. Here, the 
importance of an adequate oxygenation for the phase I metabolism is emphasized by the lack of 
an effective induction of phase I enzymatic activities in the conventional 2D cultures, which have 
been shown to force hepatocyte cultures into more anaerobic metabolic states (37). Moreover, 
the use of a complex ECM had a beneficial effect on cell survival and on maintenance of rat 
hepatocytes differentiated functions, and cultivation under controlled environment also 
prevented the loss of CYP450 inducibility as it occurred in monolayer. 
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Abstract 
 
Long term primary cultures of hepatocytes are essential for bioartificial liver (BAL) devices and 
to reduce and replace animal tests in lead candidate optimization in drug discovery and 
toxicology tests. The aim of this work was to improve bioreactor cultures of hepatocyte 
spheroids by adding a more physiological perfusion feeding regime to these bioreactor systems. 
A continuous perfusion feeding was compared with 50% medium replacement (routinely used 
for in vitro tests) at the same dilution rate, 0.125 day
-1
, for 3 operative weeks. Perfusion feeding 
led to a 10 fold improvement in albumin synthesis in bioreactors containing non-encapsulated 
hepatocyte spheroids; no significant improvement was observed in phase I drug metabolizing 
activity. When ultra high viscous alginate encapsulated spheroids were cultured in perfusion, 
urea synthesis, phase I drug metabolizing activity and oxygen consumption had a 3-fold 
improvement over the 50% medium replacement regime; albumin production was the same for 
both feeding regimes. The effective diffusion of albumin in the alginate capsules was 7.75.10
-9
 
cm
2
.s
-1
 and no diffusion limitation for this protein was observed using these alginate capsules 
under our operational conditions. In conclusion, perfusion feeding coupled with alginate 
encapsulation of hepatocyte spheroids showed a synergistic effect with a 3-fold improvement in 
three independent liver-specific functions of long-term hepatocyte spheroid cultures.  
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1. Introduction 
 
The liver has a major role in maintaining physiological homeostasis and in detoxifying blood. In 
mammals, it is responsible for nitrogen excretion in the form of urea, albumin biosynthesis (1), 
glucose storage in the form of glycogen, gluconeogenesis (2), glutamine homeostasis (3) and 
xenobiotic detoxification (4-7). 
Acute liver failure (ALF), at an approximate clinical rate of 2000 cases per year in the US (8), 
leads to death in 33% of cases. Due to liver donor scarcity, bioartificial liver (BAL) devices and 
immunoisolated xenografts of hepatocytes have been used to support these patients while 
waiting for a liver donor; nevertheless, the liver-specific functions of the hepatocytes are rapidly 
downregulated during support operation. This same problem affects primary cultured 
hepatocytes used in lead candidate optimization for drug development (5). 
ALF and drug development assays drive the need to have cells expressing liver-specific 
functions. Since the expression of several of the drug metabolizing isozymes cytochrome P450 
(CYP450), as well as nitrogen excretion and albumin synthesis, is usually downregulated in 
hepatoma or immortalized cell lines (9, 10), the main choice for BAL devices and drug 
development tests have been primary cultured hepatocytes. These cells maintain most of their 
liver-specific functions immediately after their isolation (7, 11). However, primary cultured 
hepatocytes lose their liver-specific functions along culture time (12, 13); this problem has been 
the subject of many studies whose main goal is to maintain viable and functional hepatocytes 
for longer time spans (4, 5, 14). 
Cell-cell interactions in primary cultures of hepatocytes have been shown to mimick these cells’ 
in vivo physiological structure when cultured as spheroids (15), (16, 17), including phase I and II 
xenobiotic metabolizing activities. Moreover, our group and others (18, 19) have shown that the 
entrapment of hepatocyte spheroids within alginate capsules is a promising strategy to improve 
the maintenance of liver-specific functions in vitro (20). These ultra high viscous medical grade 
alginate hydrogels have also been applied in the transplantation of insulin-
islets into immunocompetent diabetic mice (21); such capsules remained functional for more 
than one year. Alginate capsules of hepatocyte spheroids may also be used in BAL devices, 
since the capsules protect the cells from the shear stress of the high perfusion rates typical of 
these devices. 
Bioreactors provide a more controlled environment for primary cultures of hepatocytes, 
maintaining long term viability and liver-specific functionality. Some of the liver’s major 
homeostatic functions such as the regulation of glucose levels in the blood (2) or glutamine 
synthesis (22) are based on the hepatocytes’ ability to continuously sense and act upon the 
blood’s nutrient and hormone levels. Thus, when defining a culture strategy for primary cultures 
of hepatocytes, it may not be enough to simply provide enough amounts of several nutrients 
based on consumption rates; to maintain their physiological concentrations fairly constant may 
be crucial. 
Different bioreactor configurations have been developed aiming at obtaining a BAL device. 
Hollow fibers is the most common configuration for hepatocyte culture reactors (23-26) because 
these bioreactors offer immunoprotection to the ALF patient due to the separation between the 
hepatocytes and the culture medium/blood; however, this barrier also works as a disadvantage, 
since it limits mass (namely oxygen) transfer to the cells. Perfused microbioreactors with 
increased throughput capability for hepatocyte culture have recently been developed (10, 27-
31). However, these small scale devices also have inherent mass transfer limitations when 
culturing physiologically relevant 3D structures; to overcome this limitation higher perfusion 
rates are needed (due to the high cell concentration inherent to such devices), thus creating 
additional shear stress (10); it is also difficult to control essential parameters such as dissolved 
oxygen or pH in these micro systems. 
In this work, a perfusion bioreactor system was set up to maintain constant pH, temperature and 
oxygen levels, an intrinsic feature of these bioreactors (17), as well as stable concentrations of 
nutrients and hormones, assured by a gravimetric controlled perfusion system. The hepatocytes 
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were cultured as non-encapsulated spheroids or as spheroids encapsulated in highly purified, 
medical grade ultra-high viscous (20–40 mPa.s) alginate (32) to provide a shear stress free 
microenvironment. The mass transfer limitations of the alginate hydrogels were studied by 
modeling the release of albumin from the capsules. The effect of perfusion was compared to 
50% medium replacements at equivalent dilution rates. The underlying hypothesis of this work 
is that perfusion cultures have more uniform levels of nutrients, hormones and endogenously 
secreted regulators throughout the culture time, thus enabling long term maintenance of liver-
specific activities in primary cultures of hepatocyte spheroids entrapped in alginate capsules. 
The interaction between a shear stress free microenvironment, continuous feeding, no mass 
transfer limitations, 3D cell-cell interactions and controlled culture environment makes this novel 
culture system a robust tool for toxicological and drug screening tests requiring long-term 
culturing of primary hepatocytes. 
 
2. Material and Methods 
 
2.1. Rat Hepatocyte Isolation and Cell Culture 
Male Wistar rats (6-9 weeks old, with 200-300 g body weight), kept on a standard diet with free 
access to water, were obtained from Instituto de Higiene e Medicina Tropical (Lisboa). The 
isolation procedure was performed as previously described (17). Freshly isolated hepatocytes 
were cultured with Williams’E medium supplemented with 10% fetal bovine serum (FBS) (v/v), 
1.4 μM hydrocortisone, 0.032 U/mL insulin, 15 mM hepes, 1 mM sodium pyruvate, 1mM NEAA, 
antibiotics -100 U/mL penicillin /100 μg/mL streptomycin and 40 μg/mL gentamicin (WE 
complete medium). To promote cell aggregation, 30x10
6
 cells were inoculated in 200 mL WE 
complete medium with 15% FBS in 250 mL spinner vessels, initially agitated at 70 rpm, and 
kept at 37ºC in a humidified atmosphere of 5% CO2 in air for 24h. After cell aggregation (up to 
48h) the spheroids were encapsulated in alginate (see description below) and inoculated in the 
bioreactors. Working volumes ranged between 200 and 300 mL. 
To ensure a fully controlled cell culture environment, a commercially available bioreactor, 
500mL Sartorius-Stedim Biostat Q-Plus system, with a 3-blade segment stirrer was used. The 
vessel has multiple (up to twelve) upper cap ports for pH and pO2 electrodes allowing online 
measurement and control of these parameters, sampling and the addition or removal of 
medium, supplements or solutions. The pH and pO2 were controlled via surface aeration with 
Air, N2 and CO2. The pH was kept at 7.4 and the pO2 at 30% of air saturation. The temperature 
was kept at 37ºC by water recirculation in the vessel jacket controlled by a thermocirculator 
bath. The bioreactor controller unit was used to monitor and control pH, pO2 and temperature. 
Data acquisition and process control were performed using MFCS/Win Supervisory Control and 
Data Acquisition (SCADA) software (B-Braun Biotech International GmbH, Melsungen, 
Germany). 50% culture medium was replaced at 4 days intervals or exchanged by perfusion at 
an equivalent dilution rate. 
The perfusion apparatus (Figure 3.1A) included Sartorius’ Biostat Q-plus DCU unit, one port for 
the inlet (a), one custom made ceramic perfusion probe (b), one PC, the cell culture vessel, the 
inlet and outlet containers and their respective balances; pH, pO2 and temperature probes are 
not represented in Figure 3.1A. A timer-activated signal from the PC set both pumps on. The 
weight in each balance was continuously monitored through the serial port connections. When 
the decrease (inlet) or increase (outlet) of the weight reached the user-defined perfusion pulse 
threshold the pumps stopped. The outlet and inlet pumps and balances worked independently, 
thus ensuring that the same volume is added and withdrawn. The operational independence of 
the inlet and outlet systems was crucial to ensure a constant volume in the vessel, since the 
outlet flow rate (light grey line) could be lower than the inlet flow rate (dark grey line) due to filter 
resistance (Figure 3.1B, inset). 
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2.2. Cell concentration determination 
Alginate beads were dissolved by incubation in 1M Na2SO4, pH=7, at 37ºC for 20 minutes. 
Released spheroids were digested with trypsin and the resulting single cells viability was 
assessed by the trypan blue exclusion method. Cell counting was performed using a Neubauer 
counting chamber. 
2.3. Determination of albumin and urea synthesis 
The secretion of albumin from hepatocytes was measured by an enzyme-linked immunosorbent 
assay (ELISA) using NEPHRAT albumin test kit (ref.NR002, Exocell). The assay was performed 
according to the manufacturer’s description. The results were expressed as μg/day/10
6
 cells at 
the indicated time points. The urea synthesis rate was determined using a quantitative 
colorimetric urea kit (QuantiChromTM Urea Assay Kit, DIUR-500, BioAssay Systems), 
according to the manufacturer’s instructions. The albumin and urea specific synthesis rates 
were calculated according to the general mass balance equation for a continuous system: 
 
  
  
    
(       )
[  ]   
 (1) 
 
where q is the specific synthesis rate, 
  
  
 is the rate of change of the metabolite (either urea or 
albumin) in the supernatant, D is the dilution rate (0.125 day
-1
), Cin and CBR are the inlet and 
bioreactor concentrations of the metabolite and [Xv]ave is the average viable cell concentration 
during t. For the 50% medium exchange strategy D was zero and CBR was adjusted to 
account for a 50% dilution in the t where a medium exchange had occurred. The results were 
expressed as μg/day/10
6
 cells at the indicated time points. 
2.4. Glucose concentration measurement 
Glucose concentration in the culture medium was measured using the YSI 7100 analyzer 
(Yellow Spring Instruments). 
2.5. CYP450 Measurement 
7-Ethoxycoumarin (ECOD) activity was measured by the method described in Castell (33) with 
slight modifications. Salicylamide (1.5 mM), was added to the medium to prevent conjugation of 
7-hydroxy metabolites (7-HC) of 7-ethoxycoumarin. The activity is measured by the rate of 
formation of 7-hydroxycoumarin (Umbelliferone) in μmol/day/10
6
. 
2.6. Entrapment of hepatocyte spheroids in alginate 
Ultra-high viscosity, clinical grade alginates were produced and purified from strains of Lessonia 
nigrescens and Lessonia trabeculata as described elsewhere (32) (the viscosity of a 0.1% [w/v] 
solution in distilled water was 20–30 mPa.s). A 1:1 mixture of purified alginates was used at 
0.7% (w/v) in NaCl. For cell entrapment, hepatocyte spheroids were suspended in the mixture 
described above, to obtain the desired cell density per mL of alginate. Cell suspension was 
dropped through a syringe based apparatus into a solution of 20 mM BaCl2 (pH=7.3). The 
resulting spherical beads with entrapped hepatocyte spheroids were washed in 0.9% NaCl 
solution, suspended in complete medium and inoculated into the bioreactors. 
2.7. Albumin encapsulation in alginate for diffusion experiments 
To encapsulate albumin, alginate capsules were prepared similarly to spheroid capsules; 
however, instead of cells, Bovine Serum Albumin (BSA) was added to all the solutions in 
concentrations of 0.8, 1.5 and 2% (w/v), to obtain alginate capsules with these three 
concentrations. The capsules were then transferred to a PBS solution and the albumin release 
from the capsules was monitored by a fluorometrical measurement of the albumin concentration 
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in solution along time, at 37ºC, in a HORIBA Jobin-Yvon Fluoromax spectrofluorimeter 
(excitation: 280 nm, emission: 350 nm). 
To determine the diffusion coefficient of albumin in the alginate capsules eq. 2 (34, 35) was 
applied: 
   
  
   
 
  
∑
 
  
 
  (  )  
  
 
   
 (2) 
 
where Mt is the albumin concentration in solution at time t, M  is the albumin concentration in 
solution when equilibrium is reached, D is the effective diffusion of the solute inside the capsule, 
R is the average radius of the alginate capsules (200 m) and n is the number of summation 
terms used (n=6 was enough to obtain an accurate solution); this equation was fitted against the 
average fractional release (
  
  
) obtained experimentally at the three different intra-capsule 
albumin concentrations. A custom algorithm was built, using MATLAB, where a range of values 
of D where tested to solve equation (2), the chosen value being the one which minimized the 
sum of squared errors between the theoretical curve and the experimental data. It was assumed 
that there was no resistance to mass transfer due to the high ratio of solution volume to total 
capsules volume (more than 20 fold). 
2.8. Modified Dämkohler number 
The modified Dämkohler number was calculated according to the equation: 
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where Qalb is the albumin volumetric synthesis rate, in g.s
-1
.(ml alginate)
-1
, D is the diffusion 
coefficient of albumin in alginate, in cm
2
.s
-1
, R is the average radius of the alginate capsule, 0.02 
cm, and Cout and Cin are the albumin concentrations in the culture medium bulk and the albumin 
concentration inside the alginate capsule, respectively, in g.mL
-1
. 
2.9. Statistical analysis 
Unless otherwise stated, all results were subject to an ANOVA single factor analysis, with 
=0.05, using Microsoft Excell’s data analysis toolpack; p values are presented for statistically 
significant results (p<0.05, n≥3). 
 
3. Results 
 
3.1. Perfusion bioreactor set-up 
The aim of this work was to improve the functionality of hepatocyte spheroids cultured in a fully 
controlled bioreactor by continuously feeding and washing-out nutrients and secondary 
metabolites. To ensure uniform levels of nutrients, hormones and endogenously secreted 
regulators throughout culture time, a gravimetrically controlled perfusion apparatus was set-up 
(Figure 3.1) maintaining a stable, continuous dilution rate in the perfusion bioreactors. The 
perfusion cultures were compared with 50% medium exchange cultures (control) at the same 
dilution rates, by assessing their ability for long-term preservation of liver-specific phenotype. 
The effects of perfusion feeding were studied in hepatocyte spheroids alone or in a shear stress 
free microenvironment, provided by the encapsulation of the spheroids within ultra-high 
viscosity clinical grade alginate. 
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Figure 3.1 – Perfusion bioreactor system with gravimetric control. A) Perfusion apparatus (See the 
“material and methods” section for further details on the system’s operation). B) Example of 
several perfusion pulses. 
 
3.2. Perfusion bioreactor cultures of hepatocyte spheroids 
Figure 3.2B shows that the perfusion culture of non encapsulated hepatocyte spheroids 
produced over 10 fold more albumin than the control cultures after three weeks. The other liver-
specific activities analyzed, namely urea synthesis and ECOD biotransformation, were not 
significantly different between the two culture feeding strategies throughout the entire culture 
period (Figure 3.2A and D). The specific oxygen consumption rate was 1.5 fold higher in the 
control culture when compared to perfusion (Figure 3.2C, p<0.001). The improvement of 
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albumin production demonstrates the increased performance of perfusion feeding in the 
preservation of long-term liver-specific protein synthesis. 
 
 
Figure 3.2 – Effect of perfusion in the liver-specific functions of primary bioreactor cultures of non 
encapsulated hepatocyte spheroids. Urea (A) and albumin (B) synthesis rate mean values during 
the 3 weeks of culture (n was at least 3 per week, ** p<0.01) for 50% medium exchange (control, 
black bars) and perfusion (grey bars). Specific oxygen consumption rate (C) and CYP450 activity, 
measured by the metabolization of ECOD to Umbelliferone (D) in perfusion (full line, triangles) and 
50% medium exchange bioreactor culture (dashed line, squares). *** p<0.001. 
 
3.3. Perfusion bioreactor cultures of alginate entrapped hepatocyte spheroids 
Hepatocyte spheroids were encapsulated in alginate and their liver-specific phenotype was 
assessed during 3 weeks of culture. After encapsulation the alginate capsule’s diameter was 
approximately 400 m while the hepatocyte spheroids had an average diameter of 175 m 
(Figure 3.3A), making oxygen limitation inside the spheroids unlikely (36). By the time of 
encapsulation most of the cells had aggregated into compact spheroids and each capsule 
contained 1 to 2 spheroids. The capsules maintained their diameter throughout the 
experiments. 
To check if mass transfer limitations were taking place within the hepatocyte spheroids, the 
effective diffusion coefficient (D) of albumin was determined for the alginate capsules. Figure 
3.3B depicts the fractional albumin release data fitted with equation 2. The effective diffusion 
coefficient of albumin in the alginate capsules was 7.75x10
-9
 cm
2
.s
-1
 (Figure 3.3B). 
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Figure 3.3 – Characterization of ultra high viscous alginate encapsulated hepatocyte spheroids. (A) 
Phase contrast microscopy photograph of the primary cultures of rat hepatocytes at day 6, 
cultured as alginate encapsulated spheroids. Scale bar: 100 m. (B) Albumin fractional release 
from the alginate capsules; values are an average of three independent experiments with capsules 
loaded with 0.8, 1.5 and 2% (w/v) BSA. Curve was fitted with equation (2) (R
2
=0.98) and the obtained 
diffusion coefficient was 7.75x10
-9
 cm
2
.s
-1
. 
 
Figure 3.4A shows that the albumin synthesis rate of the hepatocyte cultures was not 
significantly different between the two feeding strategies. Interestingly, these rates seemed not 
to decrease along culture time, unlike the other liver-specific biosynthetic function, urea 
production, which decreased during culture (Figure 3.4B). In the second week, the perfusion 
regime allowed for higher synthesis rates than the control (p<0.05). 
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Figure 3.4 – Specific albumin A) and urea B) synthesis rates in perfusion (grey bars) and 50% 
medium exchange bioreactor culture (black bars) in primary cultures of alginate encapsulated 
hepatocyte spheroids. (n was at least 3 per week,* p<0.05). Error bars represent standard 
deviations. 
 
As shown in Figure 3.5, in the first 2 days after inoculating the hepatocytes in the bioreactors, 
both cultures increased their OCR’s; between days 3 and 12 the control bioreactor culture OCR 
decreased from 0.3 to about 0.1 nmol O2.(10
6
cells)
-1
.s
-1
, while in the perfusion bioreactor culture 
the OCR was kept at 0.4 nmol O2.(10
6
cells)
-1
.s
-1
. 
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Figure 3.5 – Specific oxygen consumption rate in perfusion (full line, triangles) and 50% medium 
exchange bioreactor culture (dashed line, squares) in primary cultures of alginate encapsulated 
hepatocyte spheroids. Brackets refer to the period between 6 and 18 culture days. *** p<0.001. 
 
The ECOD metabolization rate (CYP450 activity) was significantly enhanced in the bioreactor 
culture under the perfusion feeding regime when compared to the 50% medium replacement 
control; between days 8 and 14, with average values of 50 and 13 nmol.(10
6
cells)
-1
.day
-1
, 
respectively (Figure 3.6, p<0.001), i.e., more than 3 times higher. After 20 days the rates of 
formation of Umbelliferone were similar for both culturing regimes. 
 
 
Figure 3.6 – CYP450 activity, measured by the metabolization of ECOD to Umbelliferone, in 
perfusion (full line, triangles) and 50% medium exchange bioreactor (dashed line, squares) with 
primary cultures of alginate encapsulated hepatocyte spheroids. Brackets refer to the period 
between 7 and 12 culture days. *** p< 0.001. Error bars represent standard deviations. Lines are 3
rd
 
order polynomial fits. 
Process engineering of liver cells for drug testing applications 
51 
 
 
4. Discussion 
 
Maintaining liver-specific activities of primary cultures of hepatocytes have been attempted in 
many approaches (reviewed in (31, 37-39)). Most recent outcomes use controlled delivery of 
nutrients, namely oxygen, to the 3D cell clusters and providing a physical matrix to protect cells 
from shear stress. Our group has previously demonstrated the relevance of 3D cell-cell 
interactions and the bioreactor’s fully controlled environment (17); more recently, the beneficial 
effects of alginate entrapment in primary bioreactor cultures of hepatocyte spheroids has also 
been established (20). In this work, both these approaches have been conjugated with a 
continuous feeding strategy to further enhance the stability of the hepatocytes’ culture 
environment; the improvement resulting from the perfusion feeding, both in non-encapsulated 
as well as encapsulated hepatocyte spheroids, was compared to 50% medium replenishments 
(the control cultures) at the same dilution rate (0.125 day
-1
). 
 
The results presented herein confirm that encapsulated hepatocyte spheroids cultured under 
perfusion improved liver-specific phenotypes, except for the albumin synthesis rate, which was 
improved in non encapsulated spheroids albumin synthesis with perfusion culture (compared to 
the control). This was not due to mass transfer limitations of albumin within the alginate 
capsules; these limitations can be estimated by the calculation of a modified adimensional 
Dämkohler number, Da (equation 3), which represents the ratio between the time scales of 
albumin synthesis and diffusion, calculated for each culture time point, where. For Cin values 
ranging between 10 and 100 fold Cout, Da varies between 1.8 ± 1.4 and 0.17 ± 0.13, 
respectively, implying that the measured rates of albumin production are hardly influenced by 
limited diffusion of this protein inside the alginate capsule. This conclusion is further reinforced 
by the fact that the calculated effective diffusion coefficient is within the same magnitude of 
other literature values (34). The albumin synthesis rates achieved in the alginate entrapped 
hepatocyte spheroids, 300 g.(10
6
cells)
-1
.day
-1
 at 3 weeks culture time, are close to the 
physiological values. These may be estimated from data obtained in rat studies which report 
albumin production rates in vivo of approximately 50 mg albumin/4.6g liver/day (40); from (41, 
42) one can obtain an average yield of hepatocytes per gram of liver of 17-18 million cells. 
Thus, the in vivo albumin production rate is in the order of 700 g.(10
6
cells)
-1
.day
-1
, which 
indicates that this culture of encapsulated hepatocyte spheroids reached albumin production 
rates nearing physiological levels, independently of the feeding strategy. These near 
physiological rates are at the top end of earlier reported values which range from 100 to 300 
g.(10
6
cells)
-1
.day
-1
 in a microfabricated hepatocyte-fibroblast co-culture system (38). It is also 
worth to note that the levels of albumin synthesis rates were maintained throughout the 
encapsulated spheroid culture time; in non encapsulated cultures (both perfusion and control) 
the albumin production rates were lower, possibly reflecting the variability in protein synthesis 
between different batches of isolated rat hepatocytes; still, these values are in accordance with 
lower values found in the literature for rat hepatocyte spheroid culture (43). 
In the encapsulated spheroid culture, the specific urea synthesis rate of the perfusion regime 
was 3-fold higher than the control during the second week; values ranged from 300, in the 
beginning of the culture, to 50 g.(10
6
cells)
-1
.day
-1
, after 3 weeks. These values are in 
accordance with earlier literature reports (23, 27, 44). 
The oxygen consumption rate (OCR) in the non encapsulated 50% medium replenishment 
spheroid culture (control) was 1.5 fold higher than in the perfusion culture (Figure 3.2C). 
However, in the system using encapsulated spheroids the perfusion system enabled a 3 fold 
increase in OCR when compared to the 50% medium exchange control. This latter result 
agrees with 2 experiments investigating the consumption characteristics of rat hepatocytes 
during the first culture day, 0.38-0.6 nmol O2.(10
6
cells)
-1
.s
-1
 (45, 46); these authors also describe 
a trend for rat hepatocyte cultures to decrease their OCR along culture time. In fact, in this work, 
the OCR of both cultures reached the same value of approximately 0.25 nmol O2.(10
6
cells)
-1
.s
-1
 
after 20 days of culture (Figure 3.5). However, from day 8 to day 18 the OCR of encapsulated 
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hepatocyte spheroids cultures was, on average, 3 times higher under the perfusion feeding 
regime than the control (Figure 3.5A, p<0.001). These OCR results show that the perfusion 
culture enabled the alginate encapsulated spheroids to maintain their initial metabolic functions 
for longer than the control feeding regime.  
The activity of phase I CYP450 isozymes is quickly downregulated when hepatocytes are 
cultured ex vivo. The metabolization of ECOD by hepatocytes is mediated by more than one 
isoform of this group of enzymes, so it can be regarded as a general test for CYP450 enzymatic 
activity (47). When cultured under perfusion the encapsulated hepatocyte spheroids yielded a 3 
fold improvement in CYP450 activity over the control culture, by the second culture week, 
emphasizing the importance of maintaining a continuous feeding regime. 
The fact that perfusion feeding appears to be more critical in encapsulated cells may be 
explained by the retention of endogenously secreted extracellular matrix (ECM) components, 
which are essential for the spheroids’ cohesion within the alginate capsules. This would mask a 
possible improvement of perfusion against the 50% medium exchange strategy which would 
only become clear for the encapsulated system. To further elucidate the importance of ECM in 
the synergy between alginate encapsulation and perfusion, it would be necessary to evaluate 
the hepatocyte spheroids ECM composition (fibronectin and collagens I and IV, for instance), in 
both encapsulated and non-encapsulated systems along culture time and correlate it to the 
liver-specific phenotype obtained.  
The general 3-fold improvement obtained (CYP450 activity, OCR and Urea production rate) by 
combining the homogeneous environment provided by controlled stirred bioreactors with 
perfusion and alginate encapsulation, for primary cultures of hepatocyte spheroids, suggests 
that the simultaneous exploitation of physical, chemical and biological tools with this novel 
comprehensive strategy leads to a positive synergistic effect between alginate entrapped 
hepatocyte spheroids and the continuous feeding of culture medium. 
In comparison with the more established hollow fiber system (23, 48), it is clear that the 
absence of mass transfer limitations and the possibility of intensive hepatocyte sampling makes 
the bioreactor system described herein a better alternative to drug testing and toxicological 
studies than the hollow fiber reactors. 
It is also noteworthy that this was not only an end-point improvement, but more notably a 1 
week time extension of highly functional hepatocyte spheroid cultures. Such a system will 
certainly be an added value toward long-term studies in drug development. 
 
5. References 
 
1. Quinlan GJ, Martin GS, Evans TW. Albumin: Biochemical properties and therapeutic 
potential. Hepatology 2005;41:1211-1219. 
2. Pilkis SJ, Granner DK. MOLECULAR PHYSIOLOGY OF THE REGULATION OF 
HEPATIC GLUCONEOGENESIS AND GLYCOLYSIS. Annual Review of Physiology 
1992;54:885-909. 
3. Watford M, Chellaraj V, Ismat A, Brown P, Raman P. Hepatic glutamine metabolism. 
Nutrition 2002;18:301-303. 
4. Gebhardt R, Hengstler JG, Muller D, Glockner R, Buenning P, Laube B, Schmelzer E, 
et al. New hepatocyte in vitro systems for drug metabolism: Metabolic capacity and 
recommendations for application in basic research and drug development, standard operation 
procedures. Drug Metabolism Reviews 2003;35:145-213. 
5. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for 
studying toxicity and drug metabolism. Current Drug Metabolism 2003;4:292-312. 
6. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of 
cytochrome P450 expression and regulation. European Journal of Pharmaceutical Sciences 
2001;13:343-368. 
Process engineering of liver cells for drug testing applications 
53 
 
7. Maurel P. The use of adult human hepatocytes in primary culture and other in vitro 
systems to investigate drug metabolism in man. Advanced Drug Delivery Reviews 1996;22:105-
132. 
8. Lee WM. MEDICAL PROGRESS - ACUTE LIVER-FAILURE. New England Journal of 
Medicine 1993;329:1862-1872. 
9. Sinz M, Wallace G, Sahi J. Current industrial practices in assessing CYP450 enzyme 
induction: Preclinical and clinical. Aaps Journal 2008;10:391-400. 
10. Park J, Li Y, Berthiaume F, Toner M, Yarmush ML, Tilles AW. Radial flow hepatocyte 
bioreactor using stacked microfabricated grooved substrates. Biotechnology and Bioengineering 
2008;99:455-467. 
11. Coecke S, Rogiers V, Bayliss M, Castell J, Doehmer J, Fabre G, Fry J, et al. The use of 
long-term hepatocyte cultures for detecting induction of drug metabolising enzymes: The current 
status - ECVAM hepatocytes and metabolically competent systems task force report 1. Atla-
Alternatives to Laboratory Animals 1999;27:579-638. 
12. Nakamura T, Yoshimoto K, Nakayama Y, Tomita Y, Ichihara A. RECIPROCAL 
MODULATION OF GROWTH AND DIFFERENTIATED FUNCTIONS OF MATURE RAT 
HEPATOCYTES IN PRIMARY CULTURE BY CELL CELL CONTACT AND CELL-
MEMBRANES. Proceedings of the National Academy of Sciences of the United States of 
America-Biological Sciences 1983;80:7229-7233. 
13. Nakamura T, Tomita Y, Hirai R, Yamaoka K, Kaji K, Ichihara A. INHIBITORY EFFECT 
OF TRANSFORMING GROWTH-FACTOR-BETA ON DNA-SYNTHESIS OF ADULT-RAT 
HEPATOCYTES IN PRIMARY CULTURE. Biochemical and Biophysical Research 
Communications 1985;133:1042-1050. 
14. Vermeir M, Annaert P, Mamidi RNVS, Roymans D, Meuldermans W, Mannens G. Cell-
based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin 
Drug Metab Toxicol 2005;1:75-90. 
15. Abu-Absi SF, Friend JR, Hansen LK, Hu WS. Structural polarity and functional bile 
canaliculi in rat hepatocyte spheroids. Experimental Cell Research 2002;274:56-67. 
16. Wu F, Friend J, Remmel R, Cerra F, Hu W. Enhanced cytochrome P450 IA1 activity of 
self-assembled rat hepatocyte spheroids. Cell Transplant 1999;8:233-246. 
17. Miranda JP, Leite SB, Muller-Vieira U, Rodrigues A, Carrondo MJT, Alves PM. Towards 
an Extended Functional Hepatocyte In Vitro Culture. Tissue Engineering Part C-Methods 
2009;15:157-167. 
18. Guo XL, Yang KS, Hyun JY, Kim WS, Lee DH, Min KE, Park LS, et al. Morphology and 
metabolism of Ba-alginate-encapsulated hepatocytes with galactosylated chitosan and 
poly(vinyl alcohol) as extracellular matrices. Journal of Biomaterials Science-Polymer Edition 
2003;14:551-565. 
19. Takabatake H, Koide N, Tsuji T. ENCAPSULATED MULTICELLULAR SPHEROIDS OF 
RAT HEPATOCYTES PRODUCE ALBUMIN AND UREA IN A SPOUTED BED CIRCULATING 
CULTURE SYSTEM. Artificial Organs 1991;15:474-480. 
20. Miranda J, Rodrigues A, Tostoes R, Leite S, Zimmermann H, Carrondo M, Alves P. 
Extending hepatocyte functionality for drug testing applications using high viscosity alginate 
encapsulated 3D cultures in bioreactors. Tissue Eng Part C Methods 2010. 
21. Schneider S, Feilen P, Brunnenmeier F, Minnemann T, Zimmermann H, Zimmermann 
U, Weber M. Long-term graft function of adult rat and human islets encapsulated in novel 
alginate-based microcapsules after transplantation in immunocompetent diabetic mice. 
Diabetes 2005;54:687-693. 
22. Haussinger D, Lamers WH, Moorman AFM. HEPATOCYTE HETEROGENEITY IN THE 
METABOLISM OF AMINO-ACIDS AND AMMONIA. Enzyme 1992;46:72-93. 
23. De Bartolo L, Salerno S, Curcio E, Piscioneri A, Rende M, Morelli S, Tasselli F, et al. 
Human hepatocyte functions in a crossed hollow fiber membrane bioreactor. Biomaterials 
2009;30:2531-2543. 
24. Feng ZQ, Chu XH, Huang NP, Wang T, Wang YC, Shi XL, Ding YT, et al. The effect of 
nanofibrous galactosylated chitosan scaffolds on the formation of rat primary hepatocyte 
aggregates and the maintenance of liver function. Biomaterials 2009;30:2753-2763. 
25. Flendrig LM, laSoe JW, Jorning GGA, Steenbeek A, Karlsen OT, Bovee W, Ladiges N, 
et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally 
wound nonwoven polyester matrix for hepatocyte culture as small aggregates. Journal of 
Hepatology 1997;26:1379-1392. 
Chapter 3 – Bioreactor perfusion of 3D encapsulated hepatocytes 
54 
 
26. Patzer JF. Oxygen consumption in a hollow fiber bioartificial liver-revisited. Artificial 
Organs 2004;28:83-98. 
27. Carraro A, Hsu WM, Kulig KM, Cheung WS, Miller ML, Weinberg EJ, Swart EF, et al. In 
vitro analysis of a hepatic device with intrinsic microvascular-based channels. Biomedical 
Microdevices 2008;10:795-805. 
28. Zhang MY, Lee PJ, Hung PJ, Johnson T, Lee LP, Mofrad MRK. Microfluidic 
environment for high density hepatocyte culture. Biomedical Microdevices 2008;10:117-121. 
29. Korin N, Bransky A, Khoury M, Dinnar U, Levenberg S. Design of Well and Groove 
Microchannel Bioreactors for Cell Culture. Biotechnology and Bioengineering 2009;102:1222-
1230. 
30. Powers MJ, Janigian DM, Wack KE, Baker CS, Stolz DB, Griffith LG. Functional 
behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue 
Engineering 2002;8:499-513. 
31. Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, et al. A 
microscale in vitro physiological model of the liver: Predictive screens for drug metabolism and 
enzyme induction. Current Drug Metabolism 2005;6:569-591. 
32. Zimmermann H, Wahlisch F, Baier C, Westhoff M, Reuss R, Zimmermann D, Behringer 
M, et al. Physical and biological properties of barium cross-linked alginate membranes. 
Biomaterials 2007;28:1327-1345. 
33. Castell JV, Gómez-Lechón MJ. In vitro methods in pharmaceutical research. San Diego: 
Academic Press, 1997: ix, 467 p. 
34. Koyama K, Seki M. Evaluation of mass-transfer characteristics in alginate-membrane 
liquid-core capsules prepared using polyethylene glycol. J Biosci Bioeng 2004;98:114-121. 
35. Crank J. The mathematics of diffusion. 2d ed. Oxford, [Eng]: Clarendon Press, 1979: 
viii, 414 p. 
36. Curcio E, Salerno S, Barbieri G, De Bartolo L, Drioli E, Bader A. Mass transfer and 
metabolic reactions in hepatocyte spheroids cultured in rotating wall gas-permeable membrane 
system. Biomaterials 2007;28:5487-5497. 
37. Berthiaume F, Moghe PV, Toner M, Yarmush ML. Effect of extracellular matrix topology 
on cell structure, function, and physiological responsiveness: Hepatocytes cultured in a 
sandwich configuration. Faseb Journal 1996;10:1471-1484. 
38. Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in 
preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. 
Faseb Journal 1999;13:1883-1900. 
39. Pichard-Garcia L, Gerbal-Chaloin S, Ferrini JB, Fabre JM, Maurel P: Use of long-term 
cultures of human hepatocytes to study cytochrome P450 gene expression. In: Cytochrome 
P450, Pt C. Volume 357. San Diego: Academic Press Inc, 2002; 311-321. 
40. Peavy D, Taylor J, Jefferson L. Correlation of albumin production rates and albumin 
mRNA levels in livers of normal, diabetic, and insulin-treated diabetic rats. Proc Natl Acad Sci U 
S A 1978;75:5879-5883. 
41. Wang S, Renaud G, Infante J, Catala D, Infante R. Isolation of rat hepatocytes with 
EDTA and their metabolic functions in primary culture. In Vitro Cell Dev Biol 1985;21:526-530. 
42. Carthew P, Maronpot R, Foley J, Edwards R, Nolan B. Method for determining whether 
the number of hepatocytes in rat liver is increased after treatment with the peroxisome 
proliferator gemfibrozil. J Appl Toxicol;17:47-51. 
43. Ijima H, Kakeya Y, Yokonuma T, Hou Y, Takei T. Composition of culture medium is 
more important than co-culture with hepatic non-parenchymal cells in albumin production 
activity of primary rat hepatocytes, and the effect was enhanced by hepatocytes spheroid 
culture in collagen gel. Biochemical Engineering Journal 2009:226-231. 
44. Seagle C, Christie MA, Winnike JH, McClelland RE, Ludlow JW, O'Connell TM, 
Gamcsik MP, et al. High-throughput nuclear magnetic resonance metabolomic footprinting for 
tissue engineering. Tissue Engineering Part C-Methods 2008;14:107-118. 
45. Foy BD, Rotem A, Toner M, Tompkins RG, Yarmush ML. A DEVICE TO MEASURE 
THE OXYGEN-UPTAKE RATE OF ATTACHED CELLS - IMPORTANCE IN BIOARTIFICIAL 
ORGAN DESIGN. Cell Transplantation 1994;3:515-527. 
46. Smith MD, Smirthwaite AD, Cairns DE, Cousins RB, Gaylor JD. Techniques for 
measurement of oxygen consumption rates of hepatocytes during attachment and post-
attachment. International Journal of Artificial Organs 1996;19:36-44. 
47. Phillips IR, Shephard EA. Cytochrome P450 protocols. 2nd ed. Totowa, N.J.: Humana 
Press, 2006: xiii, 363 p. 
Process engineering of liver cells for drug testing applications 
55 
 
48. Dong J, Mandenius CF, Lubberstedt M, Urbaniak T, Nussler AKN, Knobeloch D, 
Gerlach JC, et al. Evaluation and optimization of hepatocyte culture media factors by design of 
experiments (DoE) methodology. Cytotechnology 2008;57:251-261. 
 
 
56 
 
 
 
 
Chapter 4  
 
 
 
Human liver cell spheroids in 
extended perfusion bioreactor 
culture for repeated dose drug 
testing. 
 
 
 
 
 
This Chapter was based on the manuscript: 
 
Tostoes R, Leite SB, Serra M, Jensen J, Björquist P, Carrondo M, Brito C, et al. Human liver cell 
spheroids in extended perfusion bioreactor culture for repeated dose drug testing. Hepatology 
2011. 
  
Process engineering of liver cells for drug testing applications 
57 
 
Abstract 
Primary cultures of human hepatocyte spheroids are a promising in vitro model for long term 
studies of hepatic metabolism and cytotoxicity. The lack of robust methodologies to culture cell 
spheroids, a poor characterization of the human hepatocyte spheroids architecture and liver-
specific functionality have hampered a widespread adoption of this 3D culture format. In this 
work, an automated perfusion bioreactor was used to obtain and maintain human hepatocyte 
spheroids. These spheroids were cultured for 3-4 weeks in serum-free conditions, sustaining 
their phase I enzyme expression and permitting repeated induction during long culture times; 
the rate of albumin and urea synthesis, as well as phase I and II drug metabolizing enzymes’ 
gene expression and activity of the spheroid hepatocyte cultures presented reproducible 
profiles, despite the basal inter-donor variability (n=3 donors). Immunofluorescence microscopy 
of human hepatocyte spheroids after 3-4 weeks of long term culture confirmed the presence of  
the liver-specific markers hepatocyte nuclear factor 4, albumin, cytokeratin 18 and cytochrome 
P450 3A. Moreover, immunostaining of the atypical protein kinase C apical marker, as well as 
the excretion of a fluorescent dye, evidenced that these spheroids spontaneously assemble a 
functional bile canaliculi network extending from the surface to the interior of the spheroids after 
3-4 weeks of culture. Conclusion: Perfusion bioreactor cultures of primary human hepatocyte 
spheroids maintain a liver-specific activity and architecture and are thus suitable for drug testing 
in a long term, repeated dose format.  
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1. Introduction 
 
The liver-specific functions of hepatocytes, such as albumin secretion or drug metabolizing 
activity, are rapidly downregulated during in vitro primary cultures, limiting their use for drug 
development and toxicity tests (1). For such assays, the current gold standard for long term 
human hepatocyte culture is the collagen sandwich in vitro model (2). The overlaying collagen 
layer increases cell-cell and cell-matrix contacts, providing a more 3D-like architecture than a 
monolayer culture. For rat hepatocyte spheroids, where cell-cell interactions are maximized, 
liver-specific functions (3, 4) and multicellular architecture (5, 6) are increased, when compared 
to monolayer cultures. 
The use of microfluidic devices for primary cultures of hepatocytes is a promising approach to 
enable high throughput screening in drug development (7, 8). However, the down scaling 
enabled by these technologies makes the culture environment harder to be controlled and limits 
the application of microfluidics for long term primary cultures of hepatocytes. In fact, the most 
useful applications of micro technologies for such cultures couple either microfluidic perfusion or 
co-culture micropatterning to 12 (9) or 24 well plate culture plates (10), respectively; still, these 
technologies do not enable a physiologically relevant long-term culture of primary hepatocytes. 
Bioartificial liver devices (BAL) using human hepatocytes are often built in hollow fiber formats; 
this configuration is likely among the best options for maintaining cultures of large numbers of 
hepatocytes for prolonged culture periods (11); recently, one of such devices has also been 
scaled down and adapted to drug testing, using human liver cells (12). The configuration of 
these bioreactors enables the formation of a liver-like hepatic mass throughout the culture time, 
making them long-term end point assays; nevertheless, these bioreactors were not designed for 
high throughput screening and do not allow sampling of the cellular mass throughout the culture 
period. 
CYP450 expression is downregulated during in vitro primary culture of hepatocytes; these 
enzymes are fundamental to xenobiotic metabolization studies, namely in drug development, 
and the orphan receptor-mediated induction of their mRNA synthesis is one of the most 
important parameters to be assessed in such tests (13). After these enzymes have oxidized a 
given xenobiotic, the compound is further conjugated with polar groups by phase II enzymes 
and secreted in the bile canaliculi by phase III enzymes. Thus, a long-term hepatocyte culture 
system must not only maintain CYP450 basal expression but also to enable their de novo 
mRNA synthesis upon exposure to prototypical CYP450 inducers, while maintaining the 
remaining phase II and III activities. Since phase III activity depends on the transport of phase II 
metabolites through the apical membrane, the presence of bile canaliculi is also necessary for a 
thorough assessment of drug metabolizing activity in primary cultures of hepatocytes. 
This work focuses on the use of perfusion stirred tank bioreactors for primary cultures of human 
hepatocyte as spheroids. When cultured in a bioreactor with essentially convective mass 
transfer and environmental control, the hepatocytes experience much smaller changes in pH, 
dissolved oxygen (DO) and culture medium composition than any culture system with a 
constant atmosphere and discrete medium exchanges. The pH and DO are controlled by CO2 
and N2 injection through the reactor headspace, respectively, whereas the continuous addition 
of nutrients and removal of metabolic by-products is ensured by the automated perfusion 
system (14); the good mixing minimizes the gradients of these soluble factors in the culture 
bulk. The results indicate that this bioreactor system of primary culture of human hepatocyte 
spheroids enables the robust formation of hepatic-like micro-tissue units that can be repeatedly 
induced in long-term periods. 
 
2. Material and Methods 
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2.1. Primary cultures of human hepatocytes 
Human liver samples originating from patients undergoing liver resection (Donors A, B, C and 
D), were obtained from Sahlgrenska´s Hospital (Gothenburg, Sweden) upon written consent in 
agreement with ethical approval and from the patient signed informed consent agreement. The 
human liver samples were isolated by a two-step EDTA/collagenase type IV perfusion, followed 
by slow-speed centrifugation to reduce red blood cell content. Cells were resupended in 
Williams E medium, and stored over night (shipped over night) at 4⁰ in Williams E medium 
before use. At the beginning of the experiments (upon arrival) cell viability was higher than 80% 
as determined by trypan blue exclusion, using a Fuchs-Rosenthal counting chamber. 
2.2. Perfusion Bioreactor Culture 
Primary cultures of human hepatocytes were performed in Williams’ E medium supplemented 
with 1% Glutamax, 1% Penicilin/Streptomycin (all from GIBCO/Invitrogen) and Hepatocyte 
Culture Medium (HCM) Single Quots (Lonza, Walkersville, MD) (WE). The bioreactor cultures 
were inoculated at a cell concentration of 0.2x10
6
 viable hepatocytes/ml. To promote cell 
aggregation into spheroids WE complete medium was supplemented with 10% FBS; cells were 
cultured in this medium for 72h and in serum free conditions afterwards (Figure 4.1); the 
hepatocyte culture viability after aggregation was always above 90%, as assessed by the 
Trypan Blue exclusion method. The initial bioreactor working volume (V) was 300 ml and the 
perfusion rate (F) was set to 60 ml/day; this rate was adjusted throughout the culture time (as 
the culture volume decreased due to sampling) to maintain a dilution rate (D) of 0.2 day
-1
 (i.e., 
20% medium exchange per day; D=F/V). The bioreactor (Sartorius-Stedim Biostat Q-Plus 
system) cultures were controlled at 37⁰C, pH=7.4 and DO at 30% air saturation (approximately 
60 M of O2 or 6.3% oxygen in a controlled atmosphere incubator, assuming an efficient mass 
transfer to the culture bulk). 
2.3. Hepatocyte CYP450 enzyme inductions 
Inductions of the hepatocyte spheroids’ CYP450 enzymes were performed as depicted in Figure 
4.1. Briefly, inductions in bioreactors were started by adding Rifampicin (Rif) and -
Naphtoflavone (BNF) at concentrations of 10 and 25 M, respectively. The bioreactors were 
perfused with culture medium, containing the same concentrations of both inducers, at a dilution 
rate of 0.5 day
-1
 (2.5 times the dilution rate used for normal perfusion culture), for 72h; after this 
period, culture medium was fully exchanged to ensure a complete removal of the induction 
medium. This induction procedure was performed twice, at day 3 and 2-4 weeks later, for all 
donors (Figure 4.1). 
 
Process engineering of liver cells for drug testing applications 
61 
 
 
Figure 4.1 – Experimental design of the induction of the CYP450 enzymes in primary cultures of 
hepatocyte spheroids in the bioreactor. 
 
2.4. Cell concentration determination 
Spheroids were digested with 0.05% Trypsin/EDTA (GIBCO) and the resulting single cell 
suspension viability was assessed by the Trypan Blue exclusion method. Cell counting was 
performed using a Fuchs Rosenthal counting chamber. 
2.5. Hepatocyte spheroids visualization and measurement 
Hepatocyte spheroids were visualized by phase contrast microscopy (Leica Microsystems 
GmbH, Wetzlar, Germany) and their average diameter (dave) was determined by a geometric 
mean of three diameters per spheroid using the equation dave=(d1 × d2 × d3)
1/3
; spheroid 
diameters were measured using the ImageJ software. Diameter distribution plots were done 
using the GraphPad Prism software (La Jolla, CA 92037 USA). 
2.6. Determination of albumin and urea synthesis 
The secretion of albumin from hepatocytes was measured by an enzyme-linked immunosorbent 
assay (ELISA) using the Exocell Albuwell albumin test kit (Philadelphia, PA, USA). The assay 
was performed according to the manufacturer’s description. The urea synthesis rate was 
determined using a quantitative colorimetric urea kit (QuantiChromTM Urea Assay Kit, DIUR-
500, BioAssay Systems), according to the manufacturer’s instructions. The albumin and urea 
specific synthesis rates were calculated according to the general mass balance equation for a 
continuous system: q=(∆C/∆t – D × ( Cin – Cout))/ [X]V average where q is the specific synthesis 
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rate, ∆C/∆t is the rate of change of the metabolite (either urea or albumin) in the supernatant, D 
is the dilution rate (0.2 day
-1
), Cin and Cout are the inlet and outlet concentrations of the 
metabolite and [X]V average is the average viable cell concentration during . The results were 
expressed as μg/10
6
 cells/day at the indicated time points. 
2.7. CYP450 activity Measurement 
7-Ethoxycoumarin O-deethylation (ECOD) activity was measured using the method described in 
(15) with slight modifications. Briefly,  Salicylamide (1.5 mM), was added to the medium to 
prevent conjugation of 7-hydroxy metabolites (7-HC) of 7-ethoxycoumarin. The activity is 
measured by the rate of formation of 7-hydroxycoumarin (Umbelliferone) in nmol/10
6
 cells/day. 
2.8. qRT-PCR 
Hepatocyte spheroids were collected from bioreactor cultures at different time points and stored 
at -20⁰C with RNAprotect Cell Reagent (Qiagen, Valencia, CA).  Later total RNA was extracted 
using RNEasy Plus Mini Kit   (, Qiagen) according to the manufacturer´s instructions. Reverse 
transcription was performed using 0.6ug of total RNA in a final volume of 20 ul reaction mix 
using High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems).  Real time PCR 
was performed using ready-to-use TaqMan Gene Expression Assays (applied Biosystems) 
according to the manufacturer´s instructions. GAPDH was used as endogenous control. 
2.9. Whole mount Immunofluorescence microscopy 
Hepatocyte spheroids were fixed in 4% (w/v) paraformaldehyde (PFA) in PBS for 1 hour at room 
temperature (RT), blocked overnight (O/N) at 4⁰C in 0.1 % Triton X-100 (Sigma-Aldrich) and 
0.2% fish skin gelatin solution in PBS and subsequently incubated with primary antibodies 
diluted (1:100) in 0.125% fish skin gelatine in PBS for 2 days at 4°C. Cells were washed three 
times with PBS and the secondary antibodies (diluted 1:500 in 0.125% fish skin gelatine in PBS) 
were applied to the cells overnight at 4⁰C in the dark. After three washes with PBS, the samples 
were mounted in Prolong gold anti-fade containing 4,6-diamidino-2-phenylindole (DAPI). Cells 
were visualized using point scanning (SP5, Leica Microsystems GmbH, Wetzlar, Germany) or 
spinning disk (Andor Technology, Belfast, Northern Ireland) confocal microscopy. 
2.10. CryoSection immunofluorescence microscopy 
Hepatocyte spheroids were frozen in O.C.T.
TM
 Tissue Tek (Sakura Finetek Europe, NL) and 
sectioned in 10 m thick slices onto glass coverslips. These coverslips were blocked for 10 
minutes at RT in 0.1 % Triton X-100 (Sigma-Aldrich) and 0.2% fish skin gelatin solution in PBS 
and subsequently incubated with primary antibodies diluted (1:100) in 0.125% fish skin gelatine 
in PBS for 2 hours at 4°C. Cells were washed three times with PBS and the secondary 
antibodies (diluted 1:500 in 0.125% fish skin gelatine in PBS) were applied to the cells for 1h at 
4⁰C in the dark. After three washes in PBS, the samples were mounted in Prolong gold anti-
fade containing DAPI. Cells were visualized using a Leica DMI 6000 epifluorescence 
microscope (Leica Microsystems GmbH, Wetzlar, Germany). 
2.11. Antibodies for confocal immunofluorescence microscopy 
Primary antibodies used were: goat anti-albumin, mouse anti-HNF4 (Abcam, Cambridge, UK), 
goat anti-CYP450 3A, mouse anti-aPKC (Santa Cruz, CA. 95060), FITC conjugated anti-
Cytokeratin 18 (Sigma Aldrich, St. Louis, MO), Alexa 488 conjugated Phalloidin (Molecular 
Probes, Eugene, OR) . Secundary antibodies used were anti-mouse Alexa Fluor 488, anti-goat 
Alexa Fluor 594 (Molecular Probes, Eugene, OR) and anti-mouse Cy5 (Abcam, Cambridge, 
UK). 
2.12. Bile canaliculi functionality 
Human hepatocyte spheroids were collected from the reactor after 2 weeks of culture, washed 
with PBS and incubated for 10 minutes in 2 g/ml of 5-(and-6)-carboxy-2',7'-dichlorofluorescein 
diacetate (CDFDA; Molecular Probes, Eugene, OR) in Williams E medium. Afterwards, 
spheroids were washed for 3 times with PBS and imaged in by confocal spinning disk 
microscopy (Andor Technology, Belfast, Northern Ireland). 
Process engineering of liver cells for drug testing applications 
63 
 
2.13. Statistical analysis 
Unless otherwise stated, all results were subject to an ANOVA single factor analysis, with 
=0.05, using Microsoft Excell’s data analysis toolpack; p values are presented for statistically 
significant results (p<0.05). 
 
3. Results 
 
3.1. Hepatocyte spheroid size distribution, viability and liver-specific synthesis time-course 
profiles in bioreactor cultures. 
The hepatocyte spheroid diameter is a critical variable for the maintenance of viability (16) and 
hepatic phenotype (17) in primary rat hepatocyte cultures. Thus, the average spheroid 
diameters in bioreactor cultures were measured based on phase-contrast images after 1 and 2 
weeks of culture, as depicted in Figures 4.2a and 4.2b (Donor C), yielding a size distribution plot 
as shown in Figure 4.2c. On average, the spheroid diameters were 65 ± 7 m after 1 week and 
81 ± 4 m (value ± standard error of the mean) after 2 weeks, for the 3 different donors (Figure 
4.2d), and the viability of the primary bioreactor cultures of hepatocyte spheroids was 
maintained above 70% of the inoculated viable hepatocytes without major cell death during 
culture time (Figure 4.2d).  
 
 
Figure 4.2 – Hepatocyte spheroid diameter distribution and cell viability. Bright field pictures of 
human hepatocyte spheroids in the first (a) and second (b) week of culture show an increase in 
average diameter, as quantified in c (Donor C, n= 100 spheroids; bars=200 m). The average 
diameter of the hepatocyte spheroids and the average cell culture viability (in % of viable 
inoculated hepatocytes) are depicted in d. Bars in d represent standard deviations of n= 3 donors 
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Urea and albumin secretion, two liver-specific functions essential for ammonia detoxification 
and to maintain the blood osmotic pressure, respectively, were analyzed during the hepatocyte 
spheroid bioreactor culture; Figure 4.3 shows that the time course profiles for urea (a) and 
albumin (b) synthesis were comparable and reproducible among the 3 donors. The specific 
albumin production rate increases steadily along the 15 days culture time, whereas urea 
production decreases from the onset of the culture, reaching a steady state after 1 week of 
bioreactor culture. For both liver-specific activities, as much as 10 fold inter-donor variability was 
observed. 
 
 
Figure 4.3 – Urea and albumin synthesis in bioreactor hepatocyte spheroid cultures. Bioreactor 
cultures of human hepatocyte spheroids show reproducible profiles for urea (a) and albumin (b) 
synthesis for donors A (), B () and C (). 
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3.2. Phase I and II enzyme expression and activity in bioreactor cultures. 
Hepatic drug metabolization typically involves phase I monooxygenase activity (CYP450 
activity) followed by phase II conjugation activity and the transport of hydrophilic metabolites by 
phase III transporters. The gene expression for 3 CYP450 isoforms (1A2, 2C9 and 3A4) and 2 
conjugation enzymes (GSTA1 and UGT2B7) was measured, for the 3 donors, after spheroid 
aggregation (i.e., at day 3; Figure 4.4a) and during the remaining culture time (Figure 4.4 b-d); 
in addition, 2 prototypical inducers, Rifampicin and -Naphtoflavone, were added to the cultures 
in a repeated dose (Figure 4.4 b-d, dashed boxes). Differences between donors for the gene 
expression of these drug metabolizing enzymes may vary 10-100 fold (2); this inter-donor 
variability is depicted in Figure 4.4a, where gene expression for each enzyme was normalized 
to donor C values. Thus, normalization of relative gene expression to day 3 is required to 
compare the temporal evolution of the system between donors, as depicted in Figures 4.5 b-d. 
An increase in the mRNA expression of drug metabolizing enzymes has been observed at day 
5, after the addition of the inducer cocktail (at day 3), for all donors; these expression levels 
decrease after the first induction period, for donors A and C, whereas for donor B not all 
enzymes had a reduction in expression level. The second induction period was performed 72h 
before the end of the cultures (between weeks 2 and 4), while for donors A and C cultures there 
was a general upregulation of gene expression, donor B culture only showed an increase in 
CYP3A4 mRNA after this induction. 
 
 
Figure 4.4 – Inter-donor variability and time course profiles of phase I and II enzymes in human 
hepatocyte spheroids bioreactor cultures. The gene expression of the CYP450/phase I enzymes 
1A2, 2C9  and 3A4, phase II enzymes GSTA1  and UGT2B7 was measured at day 3 (when spheroids 
were formed) and normalized to Donor A values (a); the same genes’ expression was monitored for 
the remaining culture time for donors A (b), B (c) and C (d). The gene expression values in (b, c, d) 
were normalized to the respective gene expression at day 3. CYP450 1A2 (), 2C9 (), 3A4 (); 
phase II enzymes GSTA1 () and UGT2B7 ().The dashed areas represent the induction period, 
when spheroids were exposed to both Rif (10 M) and BNF (25 M). Bars represent standard 
deviations of 3 different samples from the bioreactor. 
 
The CYP450 activity of the hepatocyte spheroids was measured by the metabolization of 7-
Ethoxycoumarin to 7-Hydroxycoumarin, a reaction mainly catalyzed by the CYP1A family, even 
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though CYP2 and CYP3 s are also involved in this deethylation reaction (18). Samples were 
collected from the bioreactors at 48 and 72h, during the first induction period (Figure 4.5); the 
ECOD activity of all the 3 donors significantly increased either by 48h (donor B), 72h (Donor A) 
or at both time points (donor C). These fold-increases ranged from 2.6 for donors A (72h) and B 
(48h) to 19 and 15 for Donor C (at 48 and 72h, respectively). 
 
 
Figure 4.5 – Induction of ECOD activity in bioreactor (see also Figure 4.1 for methodology). The 
ECOD activity of the bioreactor cultures was assessed after 48 and 72h of RIF and BNF exposure. 
Bars represent the standard error of the mean of at least 3 independent cell-based measurements; 
ANOVA was performed by comparing 0h (basal) and 48 or 72h values, for each donor. *, p<0.05; ***, 
p<0.001. 
 
3.3. Liver-specific markers and structural polarity in bioreactor cultured spheroids. 
Human hepatocyte spheroids cultured in fully controlled bioreactors, from donors A and C, were 
analyzed by immunofluorescence microscopy to assess the presence of HNF4, Cytokeratin18 
Albumin, CYP450 3A and polarity markers inside such spheroids. For donor A, both Albumin 
(Figure 4.6b, red) and CYP450 3A (Figure 4.6c, red) were still detectable at 30 days of culture, 
as well as Cytokeratin 18 (Figures 4.6b and c, green); the donor C culture stained positive for 
HNF4 after 20 days in culture (Fig. 4.6a). 
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Figure 4.6 (page 66) – Immunofluorescence microscopy of liver-specific antigens in human 
hepatocyte spheroids after 2 weeks of bioreactor culture. (a) HNF4 (green) co-localizes with the 
nuclear DAPI staining (blue); (b) albumin (red), Cytokeratin 18 (green); (c) CYP450 isoform 3A (red),  
Cytokeratin 18 (green) and nuclei (DAPI,blue). Samples for panels a and b were prepared in whole-
mount, while the samples for panel c were prepared as 10 m thick cryosections. 
 
In donor D hepatocyte spheroids, actin (phalloidin) staining (Figure 4.7a, green) shows an 
absence of stress fibers, with most of these filaments localizing at the intercellular borders; 
furthermore, an actin enrichment can be seen, in some cell-cell contacts, which forms canaliculi-
like structures (Figure 4.7a, arrow), very similar to the in vivo liver tissue architecture (19). The 
establishment of de novo polarity is more obvious when Donor C hepatocyte spheroids were 
immunostained for atypical Protein Kinase C (aPKC), a kinase associated with the apical 
domain of epithelial cells (Figure 4.7c, green): a series of 24 m confocal Z-stacks shows a bile 
canaliculi network which extends to the inner part of the spheroid (Figure 4.7c). The functionality 
of these channels was assessed by imaging the excretion of CDFDA into the canaliculi after 
being metabolized by the hepatocytes’ intracellular esterases (Figure 4.7b), in two week old 
spheroid cultures of Donor D. 
 
Chapter 4 – Human liver cell spheroids in extended perfusion bioreactor culture 
68 
 
 
Figure 4.7 – Fluorescence microscopy of structural and polarity markers and bile canaliculi function 
in human hepatocyte spheroids after 2 weeks of bioreactor culture. (a) F-actin (green) localizes to 
cell membranes and is enriched in bile-canaliculi-like structures (arrow); (b) transport of CDFDA to 
the apical (canalicular) domain of the hepatocytes shows an extensive and interconnected 
canaliculi network. (c) Confocal z-sections (numbers represent the distance from the spheroid 
surface, in m) of a hepatocyte spheroid stained for aPKC (green) and nuclei (DAPI, blue) shows 
several bile canaliculi-like channels which extend to the interior of the spheroid.  
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4. Discussion 
 
In this work, a perfused bioreactor system for long term maintenance of primary cultures of 
human hepatocyte spheroids was established and tested. In this system, hepatocyte spheroids 
reproducibly recapitulated in vivo hepatic functions and structure, despite inter-donor variability. 
We hypothesize that these reproducible time-course profiles were made possible due to the 
tight control of critical environmental variables at physiological values, such as pH and oxygen 
levels. mRNA expression of CYP450 (phase I), GSTA1 and UGT2B7 (phase II) was maintained 
up to 4 weeks and increased when the cultures were exposed to the prototypical CYP450 
inducers Rifampicin and -Naphtoflavone, in repeated dose. The phase I ECOD activity of such 
cultures also responded to such inducers, showing the system’s potential for more informative 
time course experiments. The spheroid’s inner structure resembled the liver architecture, with 
functional bile canaliculi-like structures and liver-specific markers. Such a system constitutes an 
ideal long-term culture platform for analyzing hepatic function for drug development tests.  
The formation of hepatocyte spheroids was performed during the first 72 hours of culture; phase 
contrast microscopy data of this period (data not shown) suggests an initial 24h period of cell 
clustering, when small aggregates (40-50 m) are formed; these clusters grow in size during the 
following 2 days (i.e., until 72h), as previously reported for primary cultures of rat hepatocyte 
spheroids (20). 
The influence of oxygen concentration in primary cultures of hepatocytes has been the subject 
of several publications (16, 21-23) and the conclusions from these studies are not easily 
comparable. This is mainly due to the different culture systems used, i.e., static systems (24) 
need higher oxygen concentrations for hepatocyte culture because the mass transfer relies on 
diffusion; on the other hand, stirred systems, such as the bioreactor described herein, have 
convective mass transfer and nearly homogeneous DO concentrations in the culture bulk. Thus, 
the bioreactor culture oxygen concentration used in this work (30% of air saturation in culture 
medium, i.e., 60 M) is in the interval between the known periportal and pericentral oxygen 
concentration in the rat liver, 90 and 45 M, respectively (25). 
The bulk aggregation of hepatocytes into multicellular spheroids depends on parameters such 
as the agitation type, vessel geometry (3, 26, 27) and cell inoculum (3). Brophy and colleagues 
(26) have show that rat hepatocyte spheroids could be obtained from single cells by rocking 
motion with a higher yield of spheroids (85%), when compared to rotational motion (54%). 
However, this rotational motion was based on shake flask cultures and previous work by the Hu 
group (20) had shown  that spinner vessels could yield rat hepatocyte spheroids with an 80% 
efficiency in the incorporation of single cells into spheroids, after 72h. The differences between 
the fluid dynamics in orbitally shaken flasks and spinner vessels or the different cell inoculum 
used (1 and 0.3 million hepatocytes per ml, respectively) can explain the difference in both 
publications. In the work described herein, the previous knowledge from our group concerning 
the aggregation of rat hepatocytes (3, 14, 23) was adapted to the formation of multicellular 
spheroids in primary cultures of human hepatocytes. For these cultures the control of spheroid 
size becomes critical to avoid putative nutrient diffusion limitations; in the system described 
herein, hepatocyte spheroids had an average size of 81 m (Figure 4.2d) and the number of 
spheroids with a diameter larger than 200 m was less than 0.4% of the total population (n=3 
donors). From previously published studies, it is know that rat hepatocyte spheroids with 
diameters of 100 m yield a higher albumin production rate than larger ones (17), whereas 
spheroids of up to 200 m diameter have been shown not to be subject to nutrient (namely 
oxygen) limitations (16). Since the aggregation process here described reproducibly yields 
spheroids with an average 81 m diameter, it is not expected that the hepatocytes within these 
spheroids are subject to any significant mass transfer limitations. The data obtained for liver-
specific activities (urea and albumin production, Figure 4.3; ECOD activity, Figure 4.5) and gene 
expression (CYP450 and phase II enzymes, Figure 4.4) confirm the inter-donor variability, 
which has been thoroughly described for primary human hepatocyte cultures and is a direct 
reflection of in vivo variability (1, 28); however, the tight control of critical variables by the 
perfusion bioreactor system, coupled to an easy cell sampling system, allowed reproducible 
liver-specific profiles to be obtained, despite inter-donor variability; the use of serum-free media 
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after aggregation is also a likely cause for such a reproducible behavior, since serum is known 
to downregulate both albumin synthesis and CYP450 activity of primary cultures of human 
hepatocytes (22). The profiles of urea secretion rate for the 3 donors have a significant 
decrease from the beginning of the cultures. This reduction in urea productivity has been 
observed by Zeillinger and colleagues (12, 29) in a perfusion hollow fiber bioreactor and may be 
related to the lower oxygen concentrations inside the spheroids: retrograde liver perfusion 
experiments in rats have shown that lower oxygen concentrations partially inhibit the periportal 
urea synthesis (30). 
The primary cultures of human hepatocytes in the perfusion bioreactor were inducible for the 
entire long-term period. The co-administration of Rif and BNF ensured increase in mRNA 
synthesis for CYP3A4 (Rif), CYP2C9 (Rif) and CYP1A2 (BNF) and despite the possibility of 
positive or negative synergies due to the use of both inducers, there is a significant induction in 
the 3 CYP450 isozymes; such co-administration studies constitute a unique tool to study long-
term drug-drug interactions with easy access to the hepatocytes for cell-based assays. In fact, 
the automated perfusion, as well as the oxygen and pH control in these bioreactors, can be 
used to expose primary cultures of hepatocyte spheroids to repeated drug dosing, as herein 
described, or long term time-varying drug concentrations for chronic toxicity assessment. 
The maintenance of these hepatic activities and gene expression is enabled by the cell-cell 
interactions which, during the bioreactor culture, evolve to a liver-like phenotype, as shown by 
the presence of Albumin, Cytokeratin 18, CYP450 3A and HNF4 (Figure 4.6a-c), which are 
typical hepatic markers. The structural and functional polarity shown by both actin and aPKC 
staining and CDFDA metabolization (followed by the Multidrug resistance-associated protein 2, 
MRP2,-mediated transport through the apical membrane of the hepatocytes) demonstrate that 
these human hepatocytes cultured as spheroids resume the cuboidal geometry, without actin 
stress fibers, and a polarized liver-like architecture (Figure 4.7a and c). The presence of a 
functional bile canaliculi network in the hepatocyte spheroids (Figure 4.7b), which had not been 
shown to be functional in previous studies (6), ensures an efficient polarized transport of the 
metabolic by-products in these hepatic microtissues. The similarity to in vivo liver tissue makes 
this system an interesting tool for fundamental studies of the hepatic functions in physiological 
or bioreactor-simulated pathological conditions, namely for more complex drug transport 
studies. Further improvements to this system may be achieved by adding heterotypical cell-
interactions, by co-culturing hepatocytes with endothelial cells (24) or fibroblasts (10, 23) or by 
encapsulating the hepatocyte spheroids in alginate (14). 
In conclusion, the perfusion bioreactor system presented herein allows to culture defined size 
human hepatocyte spheroids (80 m) which maintain hepatic liver-specific protein synthesis, 
CYP450, phase II and III drug metabolizing enzymes’ gene expression and activity, as well as 
liver-like architecture inside the spheroids  for 2-4 weeks. 
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Abstract 
 
A key unmet need in pharmaceutical development is reliable, available, cost-effective and 
predictive models for determining the metabolic and toxicological properties of drug compounds. 
Human hepatocytes are the regulator’s gold standard model for evaluating drug toxicity; 
however, they suffer from scarce and inconsistent availability. In vivo models are prohibitively 
expensive, have low throughput and are often not predictive for humans (1), which ultimately 
results in high failure rates and risk to volunteers in Phase I trials. 
In addition to the potential use in the pharmaceutical industry, the generation of hepatocytes for 
transplantation medicine, as a means to increase the number of functional hepatocytes in the 
liver or as a biological component for bioartificial liver (BAL) devices, make their production 
extremely attractive to the clinical industry as an alternative therapeutic approach to whole 
organ transplantation (2).   
In this work, the directed hepatic differentiation of hESC, previously developed at Cellartis AB, 
has been adapted to mimic the in vivo developmental morphogenesis; hESC-derived definitive 
endoderm cells, obtained after directed differentiation in monolayer culture, were aggregated in 
stirred tank vessels and the resulting spheroids were encapsulated in an alginate hydrogel. This 
novel differentiation process resulted in higher liver-specific gene expression, phenotype and 
activities than the monolayer cultures. 
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1. Introduction 
Although the liver is an extremely resilient organ with a remarkable regenerative capability, 
the maintenance and expansion of human hepatocytes ex vivo has proven to be a substantial 
stumbling block, with dedifferentiation and the subsequent loss of hepatic gene expression and 
function occurring within a few hours of plating (3). In order to overcome these issues, 
alternative sources of hepatocytes have been explored, namely the use of immortalised 
hepatocyte cell lines including HepG2 and Fa2N-4. Although these are a scalable resource, 
they only retain a variable set of liver-specific functions (poor liver function) not covering the 
entire spectra of biotransformation enzyme activities that occur in vivo (4). 
Human pluripotent stem cells are capable of self-renewal and differentiation in all three 
germ layers, and thereby represent a potentially inexhaustible source of somatic cells, such as 
hepatocytes. However, the differentiation of hESC to hepatocytes faces two main difficulties; on 
one hand, the differentiation process does not yield enough hepatocyte cell numbers for BAL 
applications (which require, on average, 10 billion hepatocytes); on the other hand, the final cell 
type obtained does not have a mature hepatic phenotype, namely in what concerns drug 
metabolizing enzyme activity. These two issues arise due to an inefficient differentiation process 
which results in a final population which is highly heterogeneous containing undifferentiated, 
progenitor and mature cell types (5, 6). 
Initial hepatocyte-like cell (HLC) differentiation protocols utilized the aggregation of 
hESCs in three-dimensional structures termed embryoid bodies (EBs). Whilst successful, the 
differentiation of cells through EBs resulted in mixed populations representative of all three 
germ layers (7), leading to the production of HLCs at low levels. More recently, attempts have 
been made to mimic the sequential extracellular signaling events that occur in liver development 
(8); this strategy has become known as directed differentiation and consists in the progressive 
differentiation of hESC to definitive endoderm (DE) (9, 10) and afterwards to HLCs (11). 
However, all these differentiation processes yield, at best, immature HLCs. One common 
feature of these approaches is the use of two-dimensional (2D) culture systems (5, 8, 12) for the 
hepatic maturation of hESC-derived DE cells. In liver development, even though the DE is 
established as an epithelial monolayer, further hepatic maturation proceeds through a three-
dimensional (3D) morphogenesis (13). 
Primary cultures of hepatocyte spheroids have already proven to yield higher levels of hepatic 
phenotype than 2D cultures by reproducing an in vivo environment and allowing cell-cell and 
cell-ECM interactions, which might otherwise be severely constrained or precluded entirely in 
2D cultures (14, 15); the encapsulation of such spheroids in an alginate hydrogel has also led to 
further improvement and maintenance of the hepatic phenotype in these cultures, when 
compared to control non-encapsulated spheroid cultures (16). This improvement is likely due to 
the retention of important autocrine factors such as Hepatocyte Growth Factor (HGF) or the 
ECM glycoprotein Fibronectin within the hydrogel matrix (17). 
In this work, the directed hepatic differentiation of hESC has been adapted to mimic the in vivo 
developmental morphogenesis; hESC-derived DE cells, obtained by directed differentiation in 
monolayer culture, were aggregated in agitated vessels and the resulting spheroids were 
encapsulated in an alginate hydrogel. This novel differentiation process resulted in higher liver-
specific gene expression, phenotype and activities than the monolayer cultures. 
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2. Materials and Methods 
 
2.1. Human embryonic stem cell-derived hepatic progenitor culture 
Human embryonic stem cell (hESC) line SA 181-derived hepatic progenitors (hepatic 
progenitors, day 11 of the hepatic differentiation, were resupended in KnockOut DMEM (KO-
DMEM, GIBCO/Invitrogen) and stored overnight (shipped overnight) at 4⁰ before use. At the 
beginning of the experiments (upon arrival, day 12 of the hepatic differentiation at Cellartis 
(confidential protocol)) cell viability was higher than 80% as determined by trypan blue 
exclusion, using a Fuchs-Rosenthal counting chamber. These hepatic progenitors were cultured 
in Progenitor Medium (PM) (a confidential medium formulation developed at Cellartis) for three 
days (day 15 of the hepatic differentiation); all cultures were maintained in an incubator at 37ºC 
and controlled atmosphere (5% CO2 in air). 
2.2. Optimization of spheroid formation 
2.2.1. Medium composition 
The hanging drop (HD) culture method was used to determine the best medium composition for 
the aggregation of hepatic progenitors. This HD culture system has a high throughput 96 well 
plate format which allows testing several medium compositions per drop. In the optimization 
herein described, one HD plate has been used to assess the influence of the Rock inhibitor 
(Rocki) Y-27632 (Sigma) in the aggregation of the hepatic progenitors, under the droplets 
microgravity conditions; the aggregation time was 72h, the drop volume was 20 L and each 
drop contained 1000 cells. Thus, 48 drops without Rocki were compared with the same number 
of drops using Rocki. The aggregation was evaluated by light microscopy (Leica Microsystems 
GmbH, Wetzlar, Germany). 
2.2.2. Cell aggregation process 
A single cell suspension of hepatic progenitors in PM supplemented with 10 M Rocki was 
inoculated in spinners (Wheaton, Techne, NJ, USA) with ball or paddle impeller, at 0.4 million 
cells/mL; both shake flasks (Corning, Corning, NY, USA) and Aggrewell 400 wells (Stemcell 
Technologies, Grenoble, France), were inoculated at a concentration of 1 million hepatic 
progenitors/mL. Aggrewell plates were centrifuged at 100g (as recommended by the 
manufacturer) to force the cells into the microwells. 
2.3. Spheroid measurement 
hESC-derived hepatic progenitor spheroids were visualized by phase contrast microscopy 
(Leica Microsystems GmbH, Wetzlar, Germany) and their average diameter (dave) was 
determined by a geometric mean of three diameters per spheroid (n>35 spheroids) using the 
equation dave=(d1 × d2 × d3)
1/3
; spheroid diameters were measured using the ImageJ software. 
Diameter distribution plots were done using the GraphPad Prism software (La Jolla, CA 92037 
USA). 
2.4. Alginate 
Ca2+-UP MVG alginate was dissolved by incubating the microcapsules with a chelating solution 
(50 mM EDTA and 10 mM HEPES in PBS) for 5 min at 37°C [31]. Spheroids were washed twice 
with PBS and incubated with culture medium until further analysis. 
2.5. Monolayer culture of hESC-derived hepatic progenitors 
For monolayer (2D) cultures, 6-well plates were coated with Matrigel (BD) at room temperature 
for one hour; hepatic progenitors were seeded onto these plates at 0.2 million cells/cm
2
 and 
cultured in PM supplemented with 10 M of Rocki for 24 hours. After this period the culture 
medium was changed to PM without Rocki for another 48 hours (until day 15 of the hepatic 
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differentiation). At day 16 the culture medium was changed to Maturation Medium (MM), whose 
composition was developed at Cellartis and is also confidential. This culture medium was used 
until the end of the culture, with full medium exchanges every two days. 
2.6. 3D differentiation of hESC-derived hepatic progenitors 
Hepatic progenitors (at day 12 of differentiation) were inoculated in spinner vessels with a ball 
impeller; the cells were inoculated in the vessels at a concentration of 0.4 million cells/mL in PM 
supplemented with 10 M of Rocki, at an agitation rate of 50 rpm, for 72h, i.e., up to day 15 of 
the differentiation protocol. By day 15 spheroids were separated from single cells by settling and 
encapsulated in calcium-crosslinked alginate (see below); the encapsulated spheroids were 
transferred to spinners with paddle impeller and cultured in MM until the end of the culture, with 
50% medium exchanges every two days. 
2.7. Alginate microencapsulation and dissolution 
Ultra Pure MVG alginate (UP MVG NovaMatrix, Pronova Biomedical, Oslo, Norway) was 
prepared at a concentration of 1.1% (w/v) in 0.9% (w/v) NaCl solution. Microcapsules were 
prepared by passing the alginate-cell mixture using a 1 mL syringe through an air-jet generator 
at an air flow rate of 2–3.5 L/min and an air pressure of 1 bar. These encapsulation conditions 
yielded microcapsules with a diameter of approximately 400-600 µm. For cross-linkage of the 
UP MVG alginate, a 100 mM CaCl2/10 mM HEPES solution adjusted to pH 7.4 was used. 
Alginate microcapsules were washed twice with 0.9% (w/v) NaCl solution and once with DMEM-
KO medium before being transferred to the spinner vessels (18). 
Ca
2+
-UP MVG alginate was dissolved by incubating the microcapsules with a chelating solution 
(50 mM EDTA and 10 mM HEPES in PBS) for 5 min at 37°C (18).Cells were washed twice with 
PBS and incubated with culture medium until further analysis. 
2.8. Cell concentration determination 
Hepatic progenitors monolayers were digested with TrypLE™ Select (Invitrogen, Paisley, UK), 
whereas spheroids were digested with 0.05% Trypsin/EDTA (GIBCO), for 6-8 minutes at 37ºC  
and the resulting single cell suspension viability was assessed by the trypan blue exclusion 
method. Cell counting was performed using a Fuchs Rosenthal counting chamber. 
2.9. qRT-PCR 
Hepatic progenitor spheroids and monolayer single cell suspensions were collected from the 
cultures at different time points and stored at -20⁰C with RNAprotect Cell Reagent (Qiagen, 
Valencia, CA) for up to one month. Total RNA was extracted using RNEasy Plus Mini Kit   
(Qiagen, Valencia, CA) according to the manufacturer´s instructions. Reverse transcription was 
performed using 0.6ug of total RNA in a final volume of 20 ul reaction mix using High Capacity 
cDNA Reverse Transcriptase Kit (Applied Biosystems).  Real time PCR was performed using 
ready-to-use TaqMan Gene Expression Assays (applied Biosystems) according to the 
manufacturer´s instructions. GAPDH was used as endogenous control. 
2.10. Cell membrane integrity assay. 
The qualitative assessment of the cell plasma membrane integrity during culture was performed 
using the enzyme substrate fluorescein diacetate (FDA; Sigma-Aldrich, Steinheim, Germany) 
and the DNA-dye propidium iodide (PI; Sigma-Aldrich, Steinheim, Germany) as described in the 
literature (18). Briefly, spheroids/microcapsules were incubated with 20 µg/mL FDA and 10 
µg/mL PI in PBS for 2–5 min and then observed using fluorescence microscopy (Leica 
Microsystems GmbH, Wetzlar, Germany). 
2.11. Albumin and Urea measurement 
The concentration of albumin in the culture medium supernatant was measured by an enzyme-
linked immunosorbent assay (ELISA) using the Exocell Albuwell albumin test kit (Philadelphia, 
PA, USA). The assay was performed according to the manufacturer’s description. The 
concentration of albumin in the culture medium supernatant  was determined using a 
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quantitative colorimetric urea kit (QuantiChromTM Urea Assay Kit, DIUR-500, BioAssay 
Systems), according to the manufacturer’s instructions. The supernatant concentrations were 
normalized to RNA concentration in the corresponding cellular fraction of the samples. 
 
 
3. Results 
 
3.1. Optimization of spheroid formation 
3.1.1. Medium composition 
The effect of Rocki on the aggregation of hepatic progenitors was assessed in Hanging Drop 
cultures. Figure 5.1A and B show that without this chemical agent the microgravity conditions of 
the drops are not enough to promote the aggregation of hepatic progenitors (Figure5.1 A); on 
the other hand, the presence of Rocki led to the formation of aggregation clusters (arrows, 
Figure5.1 B). Such aggregates maintained both metabolic activity and membrane integrity, 
unlike single cells, as shown in Figure 5.1C and D. 
 
Figure 5.1 – Effect of Rocki on the aggregation and viability of hepatic progenitor cells under HD 
microgravity conditions. Each 20 L drop of PM contained 1000 cells which were cultured for 72h 
in the absence (A) or presence of Rocki (B). Arrows in B indicate multicellular aggregates of cells. 
The spheroids obtained with Rocki-containing PM retained their membrane integrity and metabolic 
activity, whereas single cells did not (arrowheads), as assessed by FDA/PI staining. These are 
representative photographs of 48 Hanging Drops per condition tested; bars measure 200 and 100 
m in A-B and C-D, respectively. 
 
3.1.2. Cell aggregation process 
Several methods for increasing the efficiency of the aggregation process have been tested 
using PM supplemented with 10 M Rocki, for 72h. Figure 5.2 summarizes the conditions and 
results of this scale-up experiment. The size distribution plots show that aggregation within a 
spinner vessel with a paddle impeller or shake flasks yielded the lowest average spheroid 
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diameter (66 m), whereas the spheroids formed in a spinner with ball impeller or with 
aggrewell plates yielded larger spheroids (83 and 73 m, respectively). 
 
 
Figure 5.2 – Hardware (first column) and culture parameters (second and third column) tested for 
the optimization of the aggregation process of the hepatic progenitors; the resulting spheroids 
using each method are shown in the fourth column (A). Size distribution plots, where the horizontal 
line represents the average size of the spheroid population, for each aggregation method (B). Scale 
bars in the phase contrast photographs measure 100 m. 
 
3.2. Differentiation of hESC-derived hepatic progenitors 
A 
B 
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The workflow for the maturation of hepatic progenitors to hepatocyte-like cells is depicted in 
Figure 5.3, for 2D and 3D cultures. The 2D hepatic differentiation process is based on the 
protocol published by Brolen and colleagues (11) and the 3D differentiation process has been 
designed to match the time during which the cells are exposed to the different differentiation 
agents in both culture configurations. The hepatic progenitor spheroids formed at 72h are 
encapsulated in alginate hydrogels. 
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3.3. Hepatic progenitors viability in the 3D differentiation process 
Figure 5.4A shows that the spheroids retain their metabolic activity and membrane integrity after 
the encapsulation process; however, the membrane integrity and metabolic activity of the 
hepatic progenitor cells, in the encapsulated spheroids, indicate a decrease in the cell viability 
at differentiation day 29 (Figure 5.4C). 
 
 
Figure 5.4 – phase contrast and fluorescence microscopy images of the membrane integrity and 
metabolic activity of alginate encapsulated hepatic progenitor spheroids, assessed by the FDA/PI 
assay, at differentiation days 15 (A, post encapsulation), 23 (B, 8 day post encapsulation) and 29 
(C, 14 days post encapsulation). 
 
3.4. Urea and Albumin production 
Table 5.1 shows that both hepatic functions were present in 2D and 3D cultures, with the 3D 
cultures showing higher specific activities of Urea and Albumin secretion. 
Table 5.1 –Urea and Albumin production, normalized to the extracted RNA, at day 27 of 
differentiation. 
 Urea (g/RNA/day) Albumin (ng/RNA/day) 
2D 0.015 0.8 
3D 0.305 2.31 
 
4. Discussion 
 
Three dimensional differentiation of hESC to hepatic progenitors is typically done via embryoid 
body formation, which leads to final heterogeneous cell population. Still, embryonic and fetal 
development is a 3D process and the hypothesis underlying the work herein described was that 
the differentiation of multicellular spheroids of a hepatic-committed population of hESC would 
be more efficient than both 2D differentiation of the same initial population or a differentiation 
process of hESC embryoid bodies. 
The aggregation of hESC-derived progenitors was clearly improved by the addition of 10 M 
Rocki, as shown in Figure 5.1. Such improvement may be due to the Rocki-mediated increase 
in E-cadherin expression (19), which would enhance the cell-cell contacts that lead to spheroid 
formation. The optimization of the culture system to support the aggregation process was 
comprehensive enough to assess the importance of dynamic mixing and agitation type for 
spheroid formation; the readouts of this optimization were the amount of spheroids produced 
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(normalized to the cost) and the diameter distribution. This latter outcome was not critical since 
no spheroid exceeded 200 m. 
The poor performance of the paddle spinner for the aggregation of hESC-derived hepatic 
progenitors suggests that this agitation regime may result in shear stress levels that prevent 
aggregation. Comparing the spinner with ball impeller and the Aggrewell plate at 1 million 
cells/mL, and assuming that the differences in average diameter obtained by the 2 methods (73 
m Aggrewell vs 83 m spinner with ball impeller) are negligible, the spinner with ball impeller is 
the most cost-efficient option: the cost per million cell aggregated (assuming similar aggregation 
efficiencies) is 6-fold higher using the Aggrewell plates (calculations considering the amount of 
Rock inhibitor used and the cost of the Aggrewell plates). 
Several published works report an improvement of the liver-specific functionality of alginate 
encapsulated hepatocytes (20-23); the effects of alginate encapsulation, which include the 
protection from shear stress and the retention of ECM molecules (17), were hypothesized to 
improve the maturation of hESC-derived hepatic progenitor spheroids to hepatocyte-like cells. 
Although some improvement in Urea and Albumin secretion of such encapsulated spheroids 
could be seen (Table 5.1), when compared to the 2D hepatic maturation, there was also a 
marked decrease in cell viability (Figure 5.4) at the end of this differentiation period. This 
apparent increase in cell death may be due to the retention of proteases or other large 
molecular weight apoptotic agents. While this hypothesis can be investigated, culturing the 
progenitor spheroids without alginate encapsulation (at the expense of an increased shear 
stress at the cells’ surface) seems to be the most straightforward step in this work. 
While the optimization of spheroid formation (section 3.1) relies on statistically significant 
results, the hepatic differentiation sections (sections 3.2, 3.3 and 3.4) report one single 
experiment and must thus be viewed and discussed with caution, until the 3D differentiation 
hepatic differentiation experiments are repeated and statistically significant results are obtained. 
Since the major bottleneck in this process is the cell viability throughout the hepatic maturation, 
another strategy to be tested is the co-culture of the hESC-derived hepatic progenitors with 
human feeder cells, such as human foreskin fibroblasts (HFF), which are regularly used in 
hESC culture to maintain their undifferentiated growth (24); moreover, the co-culture of 
hepatocytes with fibroblasts is known to improve these latter cells’ liver-specific functions. 
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1. Discussion 
A key unmet need in pharmaceutical development is reliable, available, cost-effective and 
predictive models for determining the metabolic and toxicological properties of drug compounds. 
Primary cultures of human hepatocytes are FDA’s gold standard model for evaluating drug 
toxicity; however, these cells suffer from scarce and inconsistent availability. In vivo models are 
prohibitively expensive, have low throughput and are often not predictive for humans (1), which 
ultimately results in high failure rates and risk to volunteers in Phase I trials. 
The work developed in this thesis aimed to improve the liver-specific functionalities of primary 
cultures of hepatocytes (chapters 2-4) and of hESC-derived hepatic progenitors (chapter 5); 
this work has been developed taking into account the engineering challenges and critical factors 
listed in Table 1.2 (chapter 1, page 12). This table is recovered in this chapter to match the 
work developed in each chapter to the corresponding critical biological factors (Table 6.1). 
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The work developed in chapter 5 approaches the problem of the scarcity of functional hepatic 
cell types; the use of hESC-derived hepatocyte-like cells addresses this availability issue 
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because of the unlimited proliferation potential of hESC. On the other hand, the culture of these 
cells was also adapted to the 3D geometry, as was done with primary cultures of hepatocytes 
(chapters 2-4). The multicellular spheroid culture format has been used, ensuring that cell-cell, 
cell-matrix and 3D interactions were ubiquitous in this thesis. The control over the concentration 
of soluble factors has been enhanced by the addition of an automated, gravimetrically controlled 
perfusion system, as described in chapter 3, which was used in chapter 4, where this culture 
system has been validated for repeated dose drug induction studies in extended primary 
cultures of human hepatocyte spheroids. 
 
1.1. Cell culture technologies: Alginate microencapsulation and perfusion 
In chapters 2 and 3, rat hepatocyte spheroids have been entrapped in alginate hydrogels and 
cultured in biorectors. The results in chapter 2 show that alginate entrapment of hepatocyte 
spheroids increased the liver specific functionality of these cells. In chapter 3 we have 
established an automated, gravimetrically controlled perfusion bioreactor system. The effect of 
this perfusion system has been compared with discrete 50% medium exchanges, at similar 
dilution rates. Such comparison was performed with “naked” and encapsulated rat hepatocyte 
spheroids. The main observation in this work was that the impact of perfusion was different and 
more significant (regarding CYP450 activity) when spheroids were encapsulated. The 
hypothesis to explain such difference must integrate both physical and biological phenomena in 
space and time. Regarding the time, it is clear that since the dilution rates are similar, the 
depletion and build-up of beneficial or detrimental soluble factors, respectively, will tend to be 
the same for perfusion or 50% medium exchange, as the culture progresses in time. This may 
be the reason why most of the liver-specific functions have similar values by the end of the 
culture time, regardless of the spheroids being encapsulated in alginate or not. However, the 
perfusion system is expected to have a globally positive effect (when compared to discrete 
medium exchanges) on these primary cultures because i) the culture broth is maintained within 
the reactor for the entire culture time, thus avoiding the exposure of the hepatocyte spheroids to 
centrifugations and washes and ii) cells do not experience sudden shifts in the concentration of 
soluble factors. Thus, the most likely cause of non-improvement in non-encapsulated spheroid 
perfusion cultures (comparing with manual medium exchange) is the washout of the autocrine 
factors that are synthesized by the hepatocytes (Figure 6.1a and b), which limits the 
improvement that the perfusion culture could yield. 
 
Process engineering of liver cells for drug testing applications 
89 
 
 
Figure 6.1 – Working hypothesis for the synergistic effect of perfusion and alginate encapsulation in 
primary cultures of rat hepatocyte spheroids (chapter 3). A hepatocyte spheroid is represented 
either without encapsulation (a and b) or with alginate encapsulation (c and d) and with (a and c) or 
without (b and d) perfusion. The perfusion scheme does not include the inlet for the sake of 
simplification. 
 
For alginate encapsulated spheroids, it is hypothesized that such autocrine factors are retained 
inside the capsules. As was shown for albumin, it is unlikely that such retention would lead to a 
significant build-up of the soluble factors inside the capsules; however, it is certain that a 
gradient is established. Thus, the local concentration of soluble factors is expected to be higher 
at the surface of the spheroid and decrease until the alginate boundary. An experimental 
observation that has not been shown in chapter 3 is an increased cell deposition in less 
turbulent areas of the reactors, when using 50% manual exchange (in comparison with 
perfusion). Taken together, these observations suggest that ECM components may be the 
critical factors. A possible candidate within these components is Fibronectin. Given it’s 
molecular weight of 440 kDa (in the protomeric form), this molecule is likely to have a very low 
diffusivity and thus be responsible for a significant gradient within the alginate capsules. In 
addition, this glycoprotein co-polymerizes with integrin binding at the cell surface, where it forms 
a fibrilar structure which, in turn, enhances the deposition of collagens and other ECM 
molecules (2, 3). It is thus hypothesized that the increased concentration of Fibronectin at the 
spheroid surface may lead to higher rates of Fibronectin polymerization; in turn, the soluble 
Hepatocyte Growth Factor (HGF), Epidermal Growth Factor (EGF) and Transforming Growth 
Factor alfa (TGF) are also retained due to the increase in the available Fibronectin binding 
sites. This hypothesis is reinforced by Williams et al (4), which has shown that PEG hydrogels 
retain hepatocyte-synthesized Fibronectin, HGF, EGF and TGF and by the work of Fujii and 
co-workers (5); in this latter article it is shown that Polyurethane foam scaffolds, used to form rat 
hepatocyte spheroids, retain molecules with a molecular weight higher than 50 KDa which 
promote the aggregation of the rat hepatocytes. 
Phisico-Chemical
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Polymerized
ECM
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Autocrine
soluble factors
50% medium exchangeWash-out
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This washout of soluble ECM components could also be minimized in non-encapsulated 
cultures. In the absence of the retention of ECM by alginate, the diffusion boundary layer that 
surrounds the spheroids is the mass transfer barrier limiting the transport of soluble ECM 
components from the surface of the spheroid to the culture medium bulk. One option would be 
to increase this boundary layer by reducing the stirring rate; however, such stirring rate must 
ensure that the spheroids do not deposit in the bottom of the vessel. For the pitched-bladed 
impellers used throughout this work, a minimum of 60 RPM would prevent such cell deposition. 
1.1.1. Operational bottlenecks 
Despite improving the liver-specific activities of hepatocyte spheroids, alginate encapsulation 
has three disadvantages: i) cell loss during encapsulation, ii) lower cell concentration and iii) 
the fact that encapsulation is laborious and time consuming. When combined, i) and ii) result in 
a very diluted culture, which in turn leads to an increase in the volume of culture medium used; 
on the other hand, the cell loss problem becomes significantly detrimental when accounting for 
the scarcity of hepatocytes. These were the main reasons not to use alginate encapsulation for 
the validation of the perfusion bioreactor system with primary cultures of human hepatocyte 
spheroids, in chapter 4. An increase in the number of hepatocytes per volume of alginate would 
minimize all these issues, since less encapsulations would be needed (less labor and lower 
losses), while the culture would be less diluted. In a first approach, to have cell concentrations 
similar to those used in chapter 4, the number of hepatocytes per mL of alginate should be 4-
fold the current 1 million per mL of alginate, i.e., 4-5 million hepatocytes per mL of alginate. 
Such a ratio has not been tested in chapter 2, when the hepatocyte number per volume of 
alginate ratio was optimized. In fact, the values tested were 0.5, 1 and 10 million hepatocytes 
per mL of alginate; the lower value is 2-fold diluted compared to the optimal 1 million/mL 
alginate, whereas the higher value is 10-fold concentrated. 
1.2. Process validation for drug development tests: primary cultures of human hepatocytes 
and repeated dose drug induction. 
The perfusion bioreactor system has been validated for repeated dose drug induction tests in 
primary culture of human hepatocyte spheroids in chapter 4. In this work, the knowledge 
collected from rat studies has been combined with the induction of the hepatic CYP450 
enzymes in the bioreactor system. 
1.2.1. CYP450 induction in primary cultures of human hepatocytes at weeks 1-4; 
The most notable achievement in the published literature claimed hepatocyte cultures could be 
maintained for 2 weeks and has shown induction of CYP450 activity (6); furthermore, long term 
maintenance of these enzyme’s activities has been demonstrated by Zeillinger and colleagues 
(7, 8) in the Charité’s hollow fiber reactors, up to 23 days, without inducing CYP450 activity. In 
the work herein described, a repeated induction of the CYP450 enzymes was achieved in 2-4 
weeks cultures, which constitutes a clear improvement beyond the state of the art. 
1.2.2. A 3D structure which closely resembles the liver structure; 
The location of the apical marker aPKC, as well as MRP2-specific activity, has shown that these 
spheroids self-assemble to form a polarized structure, with 3D bile canaliculi. Although 
extensive references exist regarding the formation of such structures in 3D cultures (8, 9), this 
has been (to the best of our knowledge), the most clear demonstration of the three-
dimensionality of functional bile canaliculi formation in vitro. 
1.2.3. Technical inter-donor reproducibility. 
The natural variability within human hepatocyte donors was offset by reproducible time-course 
profiles of Urea and Albumin which, we hypothesize, may be attributed to the control of pH, DO, 
temperature and most soluble factor (coupled with good mixing). 
1.2.4. System limitations 
This system is currently limited by (i) the lack of data on the efficiency of spheroid formation and 
(ii) the amount of hepatocytes needed for one reactor. Regarding the first limitation (i), visual 
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inspection (by light microscopy) of the hepatocyte cultures herein described suggest that the 
aggregation efficiency is below 50%, i.e., no more than half of the inoculated hepatocytes are 
incorporated in multicellular spheroids, after 72 hours; this may be due to detrimental effects of 
collagenase digestion of the liver sample, during the isolation of the hepatocytes (10). Still, the 
large majority of viable hepatocyte preparations (from different donors) aggregate after 72h with 
10% FBS, in both stirred tank bioreactors with pitch bladed impellers and paddle impeller 
spinners. To have more quantitative data, a study should be performed using 40 m filters to 
separate single cells, doublets and triplets from multicellular spheroids and thus determine the 
efficiency of the spheroid formation process. Alternatively, the use of automated methods for 
particle measurement and counting, such as a Multisizer™ 3 COULTER COUNTER®, would 
certainly provide an accurate measurement of the aggregation efficiency. As for the high cell 
numbers used (ii), it is a problem that spawns from the scarcity of freshly isolated human 
hepatocytes; nevertheless, considering that these cells are used for drug development tests, the 
question is: how to fit this perfusion bioreactor system within the drug development pre-
clinical tests workflow? Clearly, the usefulness of this system lies on the long term 
maintenance of hepatic phenotype. One possible application, after animal tests (typically 
rodents) yield dose-toxicity information, could be to assess the long term effects of such dosing 
in the hepatic metabolism and viability in the presence (or absence) of other drugs. Moreover, 
the possibility of withdrawing a large sample from the bioreactor and subculturing in other 
systems, with higher throughput, for short term (such as shake flasks or multititer plates) or 
exposing other cell types (such as neurons or cardiac cells) to the products of the hepatic drug 
metabolism, increases the possible applications of this system. 
1.3. Human embryonic stem cells as potential source of functional hepatic cells. 
The differentiation of hESC to hepatocytes is an expanding field of research, mainly because an 
efficient differentiation process would contribute to improve the problem of human hepatocyte 
scarcity, either for BAL or drug development applications. However, the current processes and 
protocols for the hepatic differentiation of hESC yield limited numbers of non-mature 
hepatocytes, i.e., the final product lacks quantity and quality. While most of the differentiation 
protocols described in the literature (11-15) are based on the exposure of 2D cultured hESC to 
soluble factors such as HGF or Bone Morphogenetic Proteins (BMPs), the effect of 3D culture 
systems on this differentiation process has only been assessed in embryoid bodies (EBs), with 
limited success (16). In chapter 5 the effect of 3D culture on the hepatic differentiation of hESC 
has been assessed and compared with 2D cultures, using a previously published protocol (17). 
 
2. Future Work 
Although the work described in this thesis has achieved progress beyond the state of the art, 
there is still room for improvement towards an (economically viable) physiological liver culture 
system. 
2.1. Improving the hepatocyte spheroid model: co-culture 
In addition to the effect of the 3D microenvironment, it has been published that heterotypic 
interactions, provided either by stromal cells such as fibroblasts or by endothelial cells, provide 
both mechanical and biochemical stimuli that enhance liver specific functions (18, 19).  Also, 
during liver development, it is postulated that the cell contact of endothelial cells with the 
endoderm is crucial for the differentiation to liver progenitors (20, 21).  
Thus, the recreation of the 3D microenvironment associated with the effect of the heterotypic 
interactions on these culture systems may, on one hand, enhance and prolong primary 
hepatocyte functionality and, on the other hand, provide a better system for the differentiation 
process of hESC to hepatocyte-like cells. 
2.2. New hepatic cell sources 
The hepatocyte culture bioprocessing field has been developing towards the discovery and/or 
generation of new hepatic cell types, i.e., trying to overcome the logistic challenge imposed by 
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the scarcity of functional, mature human hepatocytes. The alternative cell types used in 
hepatocyte cultures for drug development or BAL applications can be immortalized/hepatoma 
cell lines (22, 23) or stem/progenitor cells (24, 25). While the former have recently been the 
subject of increased attention, mainly due to the establishment of the HepaRG cell line (26), 
progenitor cells can be originated from several donors, ensuring a diversified gene pool for drug 
testing applications. Figure 6.2 depicts the possible biological sources of hepatic cells, their 
advantages and drawbacks; not represented are the possible ethical issues that arise mainly 
with the use of hESC (derived from human embryos) and hepatoblasts (derived from fetal 
livers). Although both clinically significant cell numbers and hepatic functionality are needed, 
there is a tradeoff between the proliferative potential and the liver-specific functionality of the 
potential hepatic cell sources. Moreover, the in vitro hepatic differentiation of pluripotent cells 
derived from the bone marrow or the umbilical cord blood (and also from adipose tissue), such 
as mesenchymal stem cells (MSC), has been demonstrated (27, 28). The hepatic differentiation 
of MSC has been the subject of research as an alternative to hESC differentiation, since MSC 
do not raise ethical issues. However, the MSC derive from the mesoderm germ layer, whereas 
hepatocytes originate from the endoderm. If hESC or iPS (which are not ethically restricted) are 
used, endoderm cells can be obtained (29) and further differentiated to hepatoblasts and finally 
to hepatocytes (13). Thus, as the stem cell and developmental biology fields evolve, it is 
expected that issues such as the appropriate markers for liver progenitor cells, the effective 
plasticity of other progenitor cell types or even the reprogramming of patient-specific cell types 
may yield a cellular source of hepatocytes. At the end of the day, what will make the difference 
will be the cell numbers and the mature hepatic phenotype of the final cellular product. 
 
 
Figure 6.2 – Possible hepatic cell sources, adapted from (30) 
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3. Conclusions 
In this thesis a robust and technically reproducible system for long term, repeated dose drug 
induction tests using primary cultures of hepatocytes was developed and tested. The study of 
novel technical solutions, in chapters 2 and 3, allowed extending the bioreactor culture time of 
human hepatocyte spheroids which resume the liver-specific architecture, as described in 
chapter 4. 
The resolution of the logistic problems which is spawned by the scarcity of freshly isolated 
human hepatocytes has been approached in chapter 5, where the hepatic differentiation of 
human embryonic stem cell-derived hepatic progenitor spheroids has been studied. Three 
dimensional cell culture approaches have been used throughout this thesis, proving to be a 
critical factor in primary and stem cell culture, as well as in tissue engineering. 
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